<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7173684/results/search/disease/results.xml">
   <result pre="Egypt Knowledge Perceptions Attitude Introduction In December 2019, a rapidly" exact="infectious disease" post="emerged in Wuhan city in China. The disease was"/>
   <result pre="by a member of the family of coronaviruses, finally named" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). The highly contagious virus, which caused"/>
   <result pre="health emergency [1]. In severe cases, the virus causes fatal" exact="pneumonia" post="similar to that caused by severe acute respiratory syndrome"/>
   <result pre="the virus causes fatal pneumonia similar to that caused by" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
   <result pre="[2]. The coronaviruses have become the major pathogens of emerging" exact="respiratory disease" post="outbreaks. They represent a large family of single-stranded RNA"/>
   <result pre="single-stranded RNA viruses, which can cause illness ranging from a" exact="common cold" post="to severe symptoms like MERS and SARS [3]. The"/>
   <result pre="which is the most common symptom, cough, fatigue, malaise, and" exact="shortness" post="of breath. Global concerns about the virus have risen"/>
   <result pre="more prone to serious complications, which may be associated with" exact="acute respiratory distress syndrome" post="(ARDS) and cytokine storm [5]. Till the moment, there"/>
   <result pre="Discussion COVID-19 disease was first identified during the outbreak of" exact="severe acute respiratory syndrome" post="in Wuhan, China, in December 2019 [11]. On the"/>
   <result pre="will governments and individuals have to pay for them? The" exact="avian influenza" post="case of Indonesia, where the country supplied the samples"/>
   <result pre="governments and individuals have to pay for them? The avian" exact="influenza" post="case of Indonesia, where the country supplied the samples"/>
   <result pre="drug delivery during 100 Million Healthy Lives program to eliminate" exact="hepatitis" post="C in Egypt [31]. First, Egyptian companies got permission"/>
   <result pre="companies got permission to formulate several generic direct-acting antivirals against" exact="hepatitis" post="C at a very affordable price through an exemption"/>
   <result pre="neuroinvasive potential of SARS-CoV2 may play a role in the" exact="respiratory failure" post="of COVID-19 patientsJournal of Medical Virology202010.1002/jmv.2572832311109 3.CascellaMRajnikMCuomoAet al.Features, Evaluation"/>
   <result pre="the statusMilitary Medical Research2020711110.1186/s40779-020-00240-032169119 6.LiJYYouZWangQet al.The epidemic of 2019-novel-coronavirus (2019-nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the futureMicrobes"/>
   <result pre="of Medicine (Singapore)2008376482488 31.WakedIEsmatGElsharkawyAet al.Screening and treatemnt program to eliminate" exact="hepatitis" post="C in EgyptNew England Journal of Medicine2020382121166117410.1056/NEJMsr191262832187475 32.HaseltineWA(2020) Universal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7241448/results/search/disease/results.xml">
   <result pre="Infect Dis. 2003 Jun;9(6):713–717. doi:10.3201/eid0906.030264.12781012 3ZhouP, YangXL, WangXG, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7241531/results/search/disease/results.xml">
   <result pre="coronavirus (COVID-19) require a comprehensive understanding of humoral responses against" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), the emerging virus causing COVID-19. The"/>
   <result pre="The ongoing outbreak of 2019 novel coronavirus (COVID-19), known as" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China"/>
   <result pre="gas analysis (PaO2/FiO2 ≤ 300 mm Hg); or (d) severe disease complications including" exact="respiratory failure" post="which requires mechanical ventilation, septic shock, or non-respiratory organ"/>
   <result pre="clinical observation was also observed from a previous study of" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), in which deceased infected patients reached the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7250318/results/search/disease/results.xml">
   <result pre="Abstract ABSTRACT Lack of an appropriate animal model to study" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), the etiological agent responsible for COVID-19"/>
   <result pre="animal model for evaluating potential therapeutics and vaccine candidates for" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), the etiological agent responsible for COVID-19,"/>
   <result pre="COVID-2019, and the main drivers for registered mortality are acute" exact="respiratory failure," post="high blood pressure and cardiovascular problems which are mostly"/>
   <result pre="including the newly emerged SARS-CoV-2, are classified among the major" exact="infectious disease" post="problems and have been listed as one of the"/>
   <result pre="PeweL, Wohlford-LenaneC, et alLethal infection of K18-hACE2 mice infected with" exact="severe acute respiratory syndrome" post="coronavirus. J Virol. 2007;81:813–821.17079315 [3]YangXH, DengW, TongZ, et alMice"/>
   <result pre="[5]ShanC, YaoY-F, YangX-L, et alInfection with novel Coronavirus (SARS-CoV-2) causes" exact="pneumonia" post="in the rhesus macaques. Preprint at research square. 2020."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7317261/results/search/disease/results.xml">
   <result pre="be used. Compliance with the anti-H1N1 vaccine during the 2009" exact="influenza" post="pandemic, for instance, was low [1], and in the"/>
   <result pre="the population that needs to be immune, so that the" exact="infectious disease" post="is stable (R = 1) and is calculated as [20]: \documentclass[12pt]{minimal}"/>
   <result pre="other unvaccinated individuals than with vaccinated ones [26]. Examples of" exact="measles" post="outbreaks in the Netherlands [27] and the US [28],"/>
   <result pre="not being vaccinatedJ. Behav. Med.20194238139110.1007/s10865-018-9985-930387010 26.BarclayVCSmieszekTHeJCaoGRaineyJJGaoHet al.Positive network assortatively of" exact="influenza" post="vaccination at a high school: implications for outbreak risk"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7388780/results/search/disease/results.xml">
   <result pre="2019, the world was faced with a new coronavirus named" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease"/>
   <result pre="hit the United States and Europe the majority of our" exact="influenza" post="season was over, it is likely that we will"/>
   <result pre="to far exceed that of medical care demands during the" exact="influenza" post="seasons alone. This is attributed to three factors: first,"/>
   <result pre="first, human-to-human transmission of SARS-CoV-2 is much easier compared to" exact="influenza" post="[a basic reproduction number (Ro) of 3.6 was estimated"/>
   <result pre="is much higher than the case fatality rate for seasonal" exact="influenza" post="[3]. Recently Faust and del Rio estimated that COVID-19"/>
   <result pre="9.5–44.1-times greater than those recorded during the peak week of" exact="influenza" post="deaths during the past seven influenza seasons in the"/>
   <result pre="the peak week of influenza deaths during the past seven" exact="influenza" post="seasons in the United States, with a 20.5-fold increased"/>
   <result pre="very limited circulation of SARS-CoV-2 during the first wave. Seasonal" exact="influenza" post="is a major cause of morbidity, mortality, and use"/>
   <result pre="Organization (WHO), up to 650,000 deaths are associated with seasonal" exact="influenza" post="respiratory infections annually [9]. HCP are at increased risk"/>
   <result pre="respiratory infections annually [9]. HCP are at increased risk for" exact="influenza" post="infection, and have been often traced as sources of"/>
   <result pre="for vulnerable patients [10]. The rationale for immunizing HCP against" exact="influenza" post="relies on the need to protect them, especially those"/>
   <result pre="particularly at a time of high demand [10]. Beyond absenteeism," exact="influenza" post="immunization is expected to reduce presenteeism, which is frequent"/>
   <result pre="have been recorded [11], [12]. Beyond that, COVID-19 and seasonal" exact="influenza" post="share the same high-risk groups and both can prove"/>
   <result pre="facilities accounted for 30–60% of all COVID-19 deaths [14]. Therefore," exact="influenza" post="immunization is of critical importance for high-risk groups to"/>
   <result pre="critical importance for high-risk groups to reduce the possibility of" exact="influenza" post="infection and co-infection with SARS-CoV-2, diagnostic dilemmas, and inappropriate"/>
   <result pre="A mathematical model developed to assess the effect of mass" exact="influenza" post="immunization on the spread of COVID-19 and other respiratory"/>
   <result pre="pathogens in the case of an overlapping epidemic with the" exact="influenza" post="season, found that increasing vaccine uptake could facilitate the"/>
   <result pre="facilitate the management of respiratory outbreaks coinciding with the peak" exact="influenza" post="season, and especially, compensate for the shortage of the"/>
   <result pre="detection resources [15]. Furthermore, in the case of co-circulation of" exact="influenza" post="virus and SARS-CoV-2, high influenza vaccine uptake rates in"/>
   <result pre="the case of co-circulation of influenza virus and SARS-CoV-2, high" exact="influenza" post="vaccine uptake rates in a well-matched season between the"/>
   <result pre="vaccine uptake rates in a well-matched season between the circulating" exact="influenza" post="strains and the vaccine influenza strains, could reduce the"/>
   <result pre="well-matched season between the circulating influenza strains and the vaccine" exact="influenza" post="strains, could reduce the epidemiological noise of influenza during"/>
   <result pre="the vaccine influenza strains, could reduce the epidemiological noise of" exact="influenza" post="during the COVID-19 epidemic. Beyond strong immunization recommendations against"/>
   <result pre="immunization for the elderly and patients with chronic diseases and" exact="pertussis" post="immunization for pregnant women. Lastly, organizational or accessibility barriers"/>
   <result pre="epidemic wave, and when a COVID-19 vaccine might be available," exact="influenza" post="immunization should be regarded as integral component of preparedness"/>
   <result pre="of preparedness and response plans for the COVID-19 pandemic. Prioritizing" exact="influenza" post="immunization of pregnant women, persons with co-morbidities, the elderly,"/>
   <result pre="and residents of long-term care facilities is absolutely justified. Increasing" exact="influenza" post="vaccine uptake by HCP is also imperative in order"/>
   <result pre="call for public health authorities globally to work on raising" exact="influenza" post="vaccine uptake rates prioritizing high-risk groups and HCP. In"/>
   <result pre="groups and HCP. In countries where HCP are immunized against" exact="influenza" post="on a voluntary basis, like in almost all European"/>
   <result pre="we call upon manufacturers to insure an increased supply of" exact="influenza" post="vaccines as early in the fall season as possible"/>
   <result pre="and Dynavax. Dr. Poland holds patents related to vaccinia and" exact="measles" post="peptide vaccines. These activities have been reviewed by the"/>
   <result pre="public health policiesHealthcare42016pii:E47 11HashemiS.A.SafamaneshS.GhafouriM.TaghaviM.R.Mohajer Zadeh HeydariM.S.Namdar AhmadabadH.Co-infection with COVID-19 and" exact="influenza" post="A virus in two died patients with acute respiratory"/>
   <result pre="characteristics of critically ill patients co-infected with SARS-CoV-2 and the" exact="influenza" post="virus in WuhanChina. Int J Infect Dis96202068368732470606 13PetrilliC.M.JonesS.A.YangJ.RajagopalanH.O’ DonnellL.ChernyakY.Factors"/>
   <result pre="the EU/EEA, May 2020Euro Surveill2522202010.2807/1560-7917.ES.2020.25.22.2000956 15LiQ.TangB.BragazziN.L.XiaoY.WuJ.Modeling the impact of mass" exact="influenza" post="vaccination and public health interventions on COVID-19 epidemics with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7390283/results/search/disease/results.xml">
   <result pre="from: https://www.devex.com/news/will-vaccines-reach-low-income-countries-during-a-global-pandemic-96635 5ShangW, YangY, RaoY, RaoX. The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccines. NPJ Vaccines. 2020;5:18 Epub 2020/03/21."/>
   <result pre="(RBD) recombinant protein as a heterologous human vaccine against coronavirus" exact="infectious disease" post="(COVID)-19. Hum Vaccin Immunother. 2020:1–4. Epub 2020/04/17. 10.1080/21645515.2020.1740560 .32298218"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7405756/results/search/disease/results.xml">
   <result pre="other age groups. The pathogen that causes COVID-19 is the" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV-2), a betacoronavirus that is genetically homologous to"/>
   <result pre="been applied in epitope-carrier fusion construction in HIV vaccine and" exact="malaria" post="vaccine (19,20). The machine learning tool was used to"/>
   <result pre="unrelated pathogens (37,38). The Bacille Calmette-Guerin (BCG), a vaccine for" exact="tuberculosis" post="disease, is currently under clinical evaluation for its ability"/>
   <result pre="of the administered dose (85,86). Since COVID-19 is primarily a" exact="respiratory disease," post="establishing a mucosal immune protection is critical, indicating that"/>
   <result pre="via different mucosal routes. Tomar et al. (2019) demonstrated that" exact="hepatitis" post="B vaccine can induce high IgG titers when delivered"/>
   <result pre="but no titers when delivered intranasally, in contrast to the" exact="influenza" post="vaccine where no difference in titers was observed between"/>
   <result pre="market: Flumist®, Fluenz®, and NasoVac®. FluMist® is a live-attenuated trivalent/quadrivalent" exact="influenza" post="virus vaccine (LAIV) that consists of the influenza A"/>
   <result pre="live-attenuated trivalent/quadrivalent influenza virus vaccine (LAIV) that consists of the" exact="influenza" post="A strains H1N1 and H3N2 and two influenza B"/>
   <result pre="of the influenza A strains H1N1 and H3N2 and two" exact="influenza" post="B strains, protecting against seasonal influenza infections. European Medicines"/>
   <result pre="and H3N2 and two influenza B strains, protecting against seasonal" exact="influenza" post="infections. European Medicines Agency-approved Fluenz® is also an intranasal"/>
   <result pre="influenza infections. European Medicines Agency-approved Fluenz® is also an intranasal" exact="influenza" post="vaccine consisting of four live-attenuated strains (H1N1, H3N2, and"/>
   <result pre="vaccine consisting of four live-attenuated strains (H1N1, H3N2, and two" exact="influenza" post="B virus) developed to prevent influenza infection in individuals"/>
   <result pre="(H1N1, H3N2, and two influenza B virus) developed to prevent" exact="influenza" post="infection in individuals older than 24 months until the"/>
   <result pre="of pandemic A/California/7/2009 (H1N1) influenza. Noted that these existing intranasal" exact="influenza" post="vaccines are all cold adapted, but heat sensitive, allowing"/>
   <result pre="Song Z, et al. A new coronavirus associated with human" exact="respiratory disease" post="in China. Nature [Internet]. 2020;579(7798):265–9 Available from: http://www.nature.com/articles/s41586-020-2008-3. 2.LanJGeJYuJShanSZhouHFanSZhangQShiXWangQZhangLWangXStructure"/>
   <result pre="L, et al. Lethal infection of K18-hACE2 mice infected with" exact="severe acute respiratory syndrome" post="coronavirus. J Virol [Internet]. 2007;81(2):813–21 Available from: https://jvi.asm.org/content/81/2/813. 13.Gretebeck"/>
   <result pre="the glycoprotein of Marburg virus and the S protein of" exact="severe acute respiratory syndrome" post="coronavirus. J Virol [Internet]. 2004;78(21):12090–5 Available from: https://jvi.asm.org/content/78/21/12090. 15.Weingartl"/>
   <result pre="al. Immunization with modified Vaccinia virus Ankara-based recombinant vaccine against" exact="severe acute respiratory syndrome" post="is associated with enhanced hepatitis in ferrets. J Virol"/>
   <result pre="vaccine against severe acute respiratory syndrome is associated with enhanced" exact="hepatitis" post="in ferrets. J Virol [Internet]. 2004;78(22):12672–6 Available from: https://jvi.asm.org/content/78/22/12672."/>
   <result pre="prediction and molecular dynamics simulation of a fusion construct containing" exact="malaria" post="pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as"/>
   <result pre="al.Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses"/>
   <result pre="modification of monodisperse magnetite nanoparticles for improved intracellular uptake to" exact="breast cancer" post="cells. J Colloid Interface Sci [Internet]. 2005;283(2):352–7 Available from:"/>
   <result pre="of monodisperse magnetite nanoparticles for improved intracellular uptake to breast" exact="cancer" post="cells. J Colloid Interface Sci [Internet]. 2005;283(2):352–7 Available from:"/>
   <result pre="boerAHHagedoornPVanbeverRet al.Pulmonary immunization: deposition site is of minor relevance for" exact="influenza" post="vaccination but deep lung deposition is crucial for hepatitis"/>
   <result pre="for influenza vaccination but deep lung deposition is crucial for" exact="hepatitis" post="B vaccinationActa Pharm Sin B [Internet]2019961231124010.1016/j.apsb.2019.05.003 88.KulkarniPSRautSKDhereRMA post-marketing surveillance"/>
   <result pre="[Internet]2019961231124010.1016/j.apsb.2019.05.003 88.KulkarniPSRautSKDhereRMA post-marketing surveillance study of a human live-virus pandemic" exact="influenza" post="A (H1N1) vaccine (Nasovac ® ) in IndiaHum Vaccin"/>
   <result pre="in IndiaHum Vaccin Immunother [Internet].20139112212410.4161/hv.2231723442586 89.MutschMZhouWRhodesPBoppMChenRTLinderTSpyrCSteffenRUse of the inactivated intranasal" exact="influenza" post="vaccine and the risk of Bell’s palsy in SwitzerlandN"/>
   <result pre="palsy in SwitzerlandN Engl J Med [Internet]2004350989690310.1056/NEJMoa030595 90.MillerEAndrewsNStellitanoLStoweJWinstoneAMShneersonJet al.Risk of" exact="narcolepsy" post="in children and young people receiving AS03 adjuvanted pandemic"/>
   <result pre="children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009" exact="influenza" post="vaccine: retrospective analysisBMJ [Internet].2013346f79410.1136/bmj.f79423444425 91.ConnellTDCholera toxin, LT-I, LT-IIa and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7409616/results/search/disease/results.xml">
   <result pre="one of the European countries with the highest number of" exact="measles" post="cases in the recent past. According to this scenario,"/>
   <result pre="one of the European countries with the highest number of" exact="measles" post="cases in the recent past [3]. This issue led"/>
   <result pre="hesitancy), a percentage that reflects the international literature on general" exact="influenza" post="vaccine hesitancy [4–7]. All the comparison analysis showed that"/>
   <result pre="healthcare area: Knowledge, attitudes and behaviour towards vaccinationsClin Ter20191706e4485331696908 6.RyanKAFilippSLGurkaMJZirulnikAThompsonLAUnderstanding" exact="influenza" post="vaccine perspectives and hesitancy in university students to promote"/>
   <result pre="university students to promote increased vaccine uptakeHeliyon2019510e0260431667418 7.AbalkhailMSAlzahranyMSAlghamdiKAAlsolimanMAAlzahraniMAAlmosnedBSet al.Uptake of" exact="influenza" post="vaccination, awareness and its associated barriers among medical students"/>
   <result pre="Vaccine ShortagesInfect Control Hosp Epidemiol200526118829016320984 9.SureshPSThejaswiniVRajanTFactors associated with 2009 pandemic" exact="influenza" post="A (H1N1) vaccination acceptance among university students from India"/>
   <result pre="University of PalermoJ Prev Med Hyg2017582E93828900348 15.AfonsoNKavanaghMSwanbergSImprovement in attitudes toward" exact="influenza" post="vaccination in medical students following an integrated curricular interventionVaccine2014324502624269620"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7409819/results/search/disease/results.xml">
   <result pre="mild symptoms of the disease (such as fever, coughing and" exact="shortness" post="of breath), others develop severe disease and complications (causing"/>
   <result pre="of breath), others develop severe disease and complications (causing acute" exact="respiratory failure," post="which damages the lungs and often cause death) (Knvul"/>
   <result pre="developed a mathematical model to assess the effect of mass" exact="influenza" post="vaccination on the spread of COVID-19 and other influenza-like"/>
   <result pre="spread of COVID-19 and other influenza-like pathogens co-circulating during an" exact="influenza" post="season. Their study showed that increasing influenza vaccine uptake,"/>
   <result pre="co-circulating during an influenza season. Their study showed that increasing" exact="influenza" post="vaccine uptake, or enhancing the public health interventions, would"/>
   <result pre="large percentage of the population has become immune to the" exact="infectious disease" post="due to natural recovery from prior infection or vaccination"/>
   <result pre="the efficacy of homemade masks: Would they protect in an" exact="influenza" post="pandemic?Disaster Medicine and Public Health Preparedness7201341341824229526 DiekmannO.HeesterbeekJ.A.P.MetzJ.A.On the definition"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7410812/results/search/disease/results.xml">
   <result pre="if vaccination carries a risk of significant adverse effects (e.g.," exact="respiratory failure" post="requiring ventilation, long-term respiratory deficits) or death [1]. Disclosure"/>
   <result pre="(or have documented immunity) to influenza; tetanus, diptheria, and pertussis;" exact="hepatitis" post="B; varicella (chickenpox); and measles, mumps, and rubella. This"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7417850/results/search/disease/results.xml">
   <result pre="linger. Decisions regarding initiation or continuation of disease-modifying therapy for" exact="multiple sclerosis" post="have to consider the potential relevance to the pandemic."/>
   <result pre="More importantly, the impact of each agent on the future" exact="severe acute respiratory syndrome" post="coronavirus type-2 (SARS-CoV-2) vaccine should be carefully considered in"/>
   <result pre="vaccine should be carefully considered in treatment decisions. Moreover, some" exact="multiple sclerosis" post="therapies may have beneficial antiviral effects against SARS-CoV-2 while"/>
   <result pre="increased exposure risk and therefore may be suitable for mild" exact="multiple sclerosis" post="during the pandemic. However, moderate and highly active multiple"/>
   <result pre="multiple sclerosis during the pandemic. However, moderate and highly active" exact="multiple sclerosis" post="will continue to require treatment with oral or intravenous"/>
   <result pre="where lockdown has been removed or ameliorated. Patients with iatrogenic" exact="hypogammaglobulinemia" post="may require prophylactic intravenous immunoglobulin therapy in certain situations."/>
   <result pre="situations. When the future SARS-CoV-2 vaccine becomes available, patients with" exact="multiple sclerosis" post="should be advised that certain therapies may interfere with"/>
   <result pre="required after vaccination. They should also be aware that most" exact="multiple sclerosis" post="therapies are incompatible with live vaccines if a live"/>
   <result pre="to disease-modifying therapy during the COVID-19 pandemic. Key Points Some" exact="multiple sclerosis" post="therapeutics may increase the risk of SARS-CoV-2 infection. Some"/>
   <result pre="sclerosis therapeutics may increase the risk of SARS-CoV-2 infection. Some" exact="multiple sclerosis" post="therapeutics may have a negative impact on the future"/>
   <result pre="impact on the future SARS-CoV-2 vaccine. Clinicians should carefully select" exact="multiple sclerosis" post="therapeutics during the COVID-19 pandemic and may implement some"/>
   <result pre="mitigation strategies. Introduction Coronavirus disease 2019 (COVID-19), caused by the" exact="severe acute respiratory syndrome" post="coronavirus type-2 (SARS-CoV-2), has quickly become a global pandemic"/>
   <result pre="virus based on reports of severe infection in patients with" exact="hypogammaglobulinemia" post="due to common variable immune deficiency [12]. The difference"/>
   <result pre="the immune response can lead to immune-mediated lung damage, sepsis," exact="acute respiratory distress syndrome," post="and even death [2, 14]. Future Vaccines Against SARS-CoV-2"/>
   <result pre="neuronal inflammation. Side effects may include rare leukopenia, lymphopenia, and" exact="lymphadenopathy" post="[22, 23]. Infectious Side Effects Upper respiratory tract infections"/>
   <result pre="IFN-β treatment in patients with newly diagnosed MS. Based on" exact="influenza" post="vaccine studies, IFN-β does not seem to reduce the"/>
   <result pre="of overall infection (30% vs 28%), bronchitis (6% vs 5%)," exact="influenza" post="(14% vs 13%), nasopharyngitis (11% vs 9%), and viral"/>
   <result pre="vs 28%), bronchitis (6% vs 5%), influenza (14% vs 13%)," exact="nasopharyngitis" post="(11% vs 9%), and viral URTIs (3% vs 2%)"/>
   <result pre="potential negative impact on the protective immune response to the" exact="influenza" post="vaccine in patients taking GA but several other studies"/>
   <result pre="lymphocytes [29]. Immune side effects include rare lymphopenia (12%) and" exact="neutropenia" post="(16%) [36]. Infectious Side Effects Teriflunomide 14 mg had"/>
   <result pre="including URTIs (9% vs 7%), bronchitis (8% vs 6%), and" exact="sinusitis" post="(6% vs 4%) [36]. Rare cases of tuberculosis were"/>
   <result pre="6%), and sinusitis (6% vs 4%) [36]. Rare cases of" exact="tuberculosis" post="were also seen. There have also been reports of"/>
   <result pre="but the patient had advanced secondary progressive MS and comorbid" exact="myotonic dystrophy" post="[38]. Seven other cases of COVID-19 infection in patients"/>
   <result pre="paper surveying self-reported cases on social media [42]. Based on" exact="influenza" post="vaccine studies, teriflunomide is unlikely to reduce the protective"/>
   <result pre="experiencing lymphopenia [48]. However, there have been case reports of" exact="progressive multifocal leukoencephalopathy" post="(PML) reported with DMF mainly in patients with prolonged"/>
   <result pre="of PML. Respiratory infections including URTIs (22% vs 16% placebo)," exact="influenza" post="(12% vs 5% placebo), and sinusitis (8% vs 4%"/>
   <result pre="(22% vs 16% placebo), influenza (12% vs 5% placebo), and" exact="sinusitis" post="(8% vs 4% placebo) were commonly observed in patients"/>
   <result pre="observed in patients taking natalizumab [64]. Fatal cases of herpetic" exact="encephalitis" post="and meningitis were reported in the post-marketing data. Potential"/>
   <result pre="patients taking natalizumab [64]. Fatal cases of herpetic encephalitis and" exact="meningitis" post="were reported in the post-marketing data. Potential Relevance to"/>
   <result pre="proposed via its action on integrin receptors [6]. Based on" exact="influenza" post="vaccine studies, it is also unlikely that natalizumab will"/>
   <result pre="the CNS also raises concerns about the potential for SARS-CoV-2" exact="encephalitis" post="if natalizumab is used in patients with COVID-19 [66]."/>
   <result pre="cells, prolonged depletion of memory B cells can lead to" exact="hypogammaglobulinemia" post="in some patients as seen with other B-cell therapies"/>
   <result pre="vs 33%), lower respiratory tract infection (LRTI) (8% vs 5%)," exact="herpes zoster" post="(2.1% vs 1.0%), and herpes simplex (0.7% vs 0.1%)"/>
   <result pre="(LRTI) (8% vs 5%), herpes zoster (2.1% vs 1.0%), and" exact="herpes simplex" post="(0.7% vs 0.1%) were also higher in the ocrelizumab-treated"/>
   <result pre="may predispose recovering patients to repeated infection. Patients with ocrelizumab-related" exact="hypogammaglobulinemia" post="may be particularly vulnerable to infection-related risks [72]. Acquired"/>
   <result pre="hypogammaglobulinemia may be particularly vulnerable to infection-related risks [72]. Acquired" exact="hypogammaglobulinemia" post="in patients treated with anti-CD20 agents resembles the immune"/>
   <result pre="with intravenous immunoglobulin should be considered in patients with severe" exact="hypogammaglobulinemia" post="as a prophylactic measure in uninfected patients and to"/>
   <result pre="of T cells, alemtuzumab can cause several autoimmune disorders including" exact="thyroid disease," post="idiopathic thrombocytopenia, and glomerulonephritis. Alemtuzumab also alters the innate"/>
   <result pre="CD52-positive macrophages and dendritic cells [85]. It can also cause" exact="neutropenia" post="and pancytopenia. Infectious Side Effects Patients treated with alemtuzumab"/>
   <result pre="vs 53% of patients taking IFN-β1a [86]. These infections included" exact="nasopharyngitis" post="(25% vs 19%), URTIs (16% vs 13%), sinusitis (11%"/>
   <result pre="infections included nasopharyngitis (25% vs 19%), URTIs (16% vs 13%)," exact="sinusitis" post="(11% vs 8%), herpetic infections (16% vs 3%), influenza"/>
   <result pre="13%), sinusitis (11% vs 8%), herpetic infections (16% vs 3%)," exact="influenza" post="(8% vs 6%), and bronchitis (7% vs 4%). Serious"/>
   <result pre="taking alemtuzumab vs 1% of patients taking IFN-β1a. These included" exact="pneumonia" post="and herpes zoster. Potential Relevance to the COVID-19 Pandemic"/>
   <result pre="vs 1% of patients taking IFN-β1a. These included pneumonia and" exact="herpes zoster." post="Potential Relevance to the COVID-19 Pandemic and Possible Risk"/>
   <result pre="infection is the link between alemtuzumab and the risk of" exact="stroke" post="and cervicocephalic arterial dissection [92, 93]. This might augment"/>
   <result pre="the innate immune cells is limited, although rare cases of" exact="neutropenia" post="and pancytopenia have been described. Lymphocyte counts are monitored"/>
   <result pre="immune cells is limited, although rare cases of neutropenia and" exact="pancytopenia" post="have been described. Lymphocyte counts are monitored regularly prior"/>
   <result pre="in the placebo group. There was a higher incidence of" exact="herpes zoster" post="infections in patients with severe lymphopenia of less than"/>
   <result pre="with severe lymphopenia of less than 500/mm3. Severe and fatal" exact="tuberculosis" post="and hepatitis B infections have occurred with cladribine. Potential"/>
   <result pre="lymphopenia of less than 500/mm3. Severe and fatal tuberculosis and" exact="hepatitis" post="B infections have occurred with cladribine. Potential Relevance to"/>
   <result pre="risk mitigation strategies Interferon-beta Modulate T/B cells and cytokines Rare" exact="leukopenia" post="and lymphadenopathy Once weekly IM, once every 2 weeks"/>
   <result pre="strategies Interferon-beta Modulate T/B cells and cytokines Rare leukopenia and" exact="lymphadenopathy" post="Once weekly IM, once every 2 weeks SC, 3"/>
   <result pre="continue – Teriflunomide Decrease proliferation of reactive lymphocytes Rare lymphopenia," exact="neutropenia" post="Once daily orally May increase susceptibility Possible antiviral effect"/>
   <result pre="are JCV antibody negative No, may continue but monitor for" exact="encephalitis" post="Consider an extended-dosing interval to reduce exposure risk Ocrelizumab"/>
   <result pre="reduce exposure risk Ocrelizumab Anti-CD20 causing selective B-cell depletion Lymphopenia," exact="hypogammaglobulinemia" post="6-monthly infusions May increase susceptibility and reinfection risk –"/>
   <result pre="deficiency Check post-vaccination serology Alemtuzumab Anti-CD52 causing non-selective lymphopenia Neutropenia," exact="pancytopenia" post="Daily IV for 5 days then daily IV for"/>
   <result pre="causing non-selective lymphopenia with more impact on B cells Neutropenia," exact="pancytopenia" post="Oral: two courses 1 year apart each made of"/>
   <result pre="John Cunningham virus, MHC major histocompatibility complex, PPMS primary progressive" exact="multiple sclerosis," post="RMS relapsing multiple sclerosis, S1P sphingosine-1-phosphate, SARS-CoV-2 severe acute"/>
   <result pre="major histocompatibility complex, PPMS primary progressive multiple sclerosis, RMS relapsing" exact="multiple sclerosis," post="S1P sphingosine-1-phosphate, SARS-CoV-2 severe acute respiratory syndrome coronavirus type-2,"/>
   <result pre="progressive multiple sclerosis, RMS relapsing multiple sclerosis, S1P sphingosine-1-phosphate, SARS-CoV-2" exact="severe acute respiratory syndrome" post="coronavirus type-2, SC subcutaneously Fig. 1 Proposed practical approach"/>
   <result pre="Ig immunoglobulin, IVIG intravenous immunoglobulins, JCV John Cunningham virus, MS" exact="multiple sclerosis" post="Declarations Funding No sources of funding were received for"/>
   <result pre="on the mechanism of cytokine storm induced by new coronavirus" exact="pneumonia" post="and related immunotherapyZhonghua Shao Shang Za Zhi202036E005 8.VabretNBrittonGJGruberCet al.Immunology"/>
   <result pre="elicited by SARS-CoV-2 infectionNature202032454513 11.SoresinaAMorattoDChiariniMet al.Two X-linked agammaglobulinemia patients develop" exact="pneumonia" post="as COVID-19 manifestation but recoverPediatr Allergy Immunol202032319118 12.QuintiILougarisVMilitoCet al.A"/>
   <result pre="phase 2 trialLancet2020395102381695170432401715 26.SchwidSRDeckerMDLopez-BresnahanMcollab: Rebif-Influenza Vaccine Study InvestigatorsImmune response to" exact="influenza" post="vaccine is maintained in patients with multiple sclerosis receiving"/>
   <result pre="InvestigatorsImmune response to influenza vaccine is maintained in patients with" exact="multiple sclerosis" post="receiving interferon beta-1aNeurology200565121964196616380621 27.CohenJABarkhofFComiGet al.Oral fingolimod or intramuscular interferon"/>
   <result pre="https://www.copaxone.com/globalassets/copaxone/prescribing-information.pdf. Accessed 28 July 2020. 31.PellegrinoPCarnovaleCPerroneVet al.Efficacy of vaccination against" exact="influenza" post="in patients with multiple sclerosis: the role of concomitant"/>
   <result pre="and predictors of response to a single dose trivalent seasonal" exact="influenza" post="vaccine in multiple sclerosis patients receiving disease-modifying therapiesCNS Neurosci"/>
   <result pre="response to a single dose trivalent seasonal influenza vaccine in" exact="multiple sclerosis" post="patients receiving disease-modifying therapiesCNS Neurosci Ther201925224525430044050 33.OlbergHKEideGECoxRJet al.Antibody response"/>
   <result pre="receiving disease-modifying therapiesCNS Neurosci Ther201925224525430044050 33.OlbergHKEideGECoxRJet al.Antibody response to seasonal" exact="influenza" post="vaccination in patients with multiple sclerosis receiving immunomodulatory therapyEur"/>
   <result pre="33.OlbergHKEideGECoxRJet al.Antibody response to seasonal influenza vaccination in patients with" exact="multiple sclerosis" post="receiving immunomodulatory therapyEur J Neurol201825352753429205701 34.FoxRJMillerDHPhillipsJTet al.Placebo controlled, phase"/>
   <result pre="symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to" exact="multiple sclerosis" post="relapseJ Neurol202032494855 41.LucaBTommasoGBavaroDFet al.Seroconversion and indolent course of COVID-19"/>
   <result pre="41.LucaBTommasoGBavaroDFet al.Seroconversion and indolent course of COVID-19 in patients with" exact="multiple sclerosis" post="treated with fingolimod and teriflunomideJ Neurol Sci202041611701132650143 42.NesbittCRathLYehWZet al.MSCOVID19:"/>
   <result pre="Scler Relat Disord20204510233832629402 43.Bar-OrAFreedmanMSKremenchutzkyMet al.Teriflunomide effect on immune response to" exact="influenza" post="vaccine in patients with multiple sclerosisNeurology201381655255823851964 44.O’ConnorPWolinskyJSConfavreuxCet al.Randomized trial"/>
   <result pre="Engl J Med2011365141293130321991951 45.ConfavreuxCO’ConnorPComiGet al.Oral teriflunomide for patients with relapsing" exact="multiple sclerosis" post="(TOWER): a randomized, double-blind, placebo-controlled, phase 3 trialLancet Neurol201413324725624461574"/>
   <result pre="October 2019. https://www.vumerityhcp.com/content/dam/commercial/vumerity/hcp/en_us/pdf/vumerity-prescribing-information.pdf. Accessed 28 July 2020. 49.DieboldMAltersbergerVDécardBFKapposLDerfussTLorscheiderJA case of" exact="progressive multifocal leukoencephalopathy" post="under dimethyl fumarate treatment without severe lymphopenia or immunosenescenceMult"/>
   <result pre="al.Safety and efficacy of ozanimod versus interferon beta-1a in relapsing" exact="multiple sclerosis" post="(RADIANCE): a multicentre, randomised, 24-month, phase 3 trialLancet Neurol201918111021103331492652"/>
   <result pre="57.Valencia-SanchezCWingerchukDMA fine balance: immunosuppression and immunotherapy in a patient with" exact="multiple sclerosis" post="and COVID-19Mult Scler Relat Disord20204210218232416330 58.FoxEJBuckleGJSingerBSinghVBosterALymphopenia and DMTs for"/>
   <result pre="management considerationsNeuro Ther20198241250 60.BarzegarMMirmosayyebONehzatNet al.COVID-19 infection in a patient with" exact="multiple sclerosis" post="treated with fingolimodNeurol Neuroimmunol Neuroinflamm202074e75332371550 61.FoerchCFriedauerLBauerBWolfTAdamEHSevere COVID-19 infection in"/>
   <result pre="fingolimodNeurol Neuroimmunol Neuroinflamm202074e75332371550 61.FoerchCFriedauerLBauerBWolfTAdamEHSevere COVID-19 infection in a patient with" exact="multiple sclerosis" post="treated with fingolimodMult Scler Relat Disord20204210218032408155 62.ChiariniMPagheraSMorattoDet al.Immunologic characterization"/>
   <result pre="fingolimodMult Scler Relat Disord20204210218032408155 62.ChiariniMPagheraSMorattoDet al.Immunologic characterization of a immunosuppressed" exact="multiple sclerosis" post="patient that recovered from SARS-CoV-2 infectionJ Neuroimmunol202034557728232505908 63.KapposLMehlingMArroyoRet al.Randomized"/>
   <result pre="2019. https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf?cid=PPC-MICROSOFT-Tysabri_DTC_Branded_Phrase~S~PH~BR~NER~DTC~BR-natalizumab-NA-p31547638597&amp;amp;&amp;amp;msclkid=ba0b5edf571d1d26140801cd7edd34cb&amp;amp;gclid=ba0b5edf571d1d26140801cd7edd34cb&amp;amp;gclsrc=3p.ds. Accessed 28 July 2020. 65.VågbergMKumlinUSvenningssonAHumoral immune response to" exact="influenza" post="vaccine in natalizumab-treated MS patientsNeurol Res201234773073322709910 66.GiovannoniGHawkesCLechner-ScottJLevyMWaubantEGoldJThe COVID-19 pandemic"/>
   <result pre="approachMult Scler Relat Disord20204110216532388451 69.AguirreCMeca-LallanaVBarrios-BlandinoADel RíoBVivancosJCovid-19 in a patient with" exact="multiple sclerosis" post="treated with natalizumab: may the blockade of integrins have"/>
   <result pre="infections in the pivotal phase III trials of ocrelizumab in" exact="multiple sclerosis" post="and their open-label extensions. Paper presented at the 2019"/>
   <result pre="may affect susceptibility to acute respiratory illness among patients with" exact="multiple sclerosis" post="during the early COVID-19 epidemic in IranMult Scler Relat"/>
   <result pre="COVID-19 epidemic in IranMult Scler Relat Disord20204310219532460086 76.Meca-LallanaVAguirreCRíoBCardeñosoLAlarconTVivancosJCOVID-19 in 7" exact="multiple sclerosis" post="patients in treatment with ANTI-CD20 therapiesMult Scler Relat Disord20204410230632585617"/>
   <result pre="with hypogammaglobulinemiaMult Scler Relat Disord20204410231532593144 80.Van AssenSHolvastABenneCAet al.Humoral responses after" exact="influenza" post="vaccination are severely reduced in patients with rheumatoid arthritis"/>
   <result pre="responses after influenza vaccination are severely reduced in patients with" exact="rheumatoid arthritis" post="treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with multiple"/>
   <result pre="after influenza vaccination are severely reduced in patients with rheumatoid" exact="arthritis" post="treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with multiple"/>
   <result pre="rheumatoid arthritis treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with" exact="multiple sclerosis" post="treated with ocrelizumab: a pharmacovigilance case seriesMult Scler Relat"/>
   <result pre="pharmacovigilance case seriesMult Scler Relat Disord202032570202 82.Montero-EscribanoPMatías-GuiuJGómez-IglesiasPPorta-EtessamJPytelVMatias-GuiuJAAnti-CD20 and COVID-19 in" exact="multiple sclerosis" post="and related disorders: a case series of 60 patients"/>
   <result pre="Relat Disord20204210212032315980 84.GhajarzadehMMirmosayyebOBarzegarMet al.Favorable outcome after COVID-19 infection in a" exact="multiple sclerosis" post="patient initiated on ocrelizumab during the pandemicMult Scler Relat"/>
   <result pre="28 July 2020. 87.GuevaraCVillaECifuentesMNavesRGraziaJMild COVID-19 infection in a patient with" exact="multiple sclerosis" post="and severe depletion of T-lymphocyte subsets due to alemtuzumabMult"/>
   <result pre="subsets due to alemtuzumabMult Scler Relat Disord20204410231432593959 88.CarandiniTPietroboniAMSacchiLet al.Alemtuzumab in" exact="multiple sclerosis" post="during the COVID-19 pandemic: a mild uncomplicated infection despite"/>
   <result pre="intense immunosuppressionMult Scler202032463329 89.Matías-GuiuJMontero-EscribanoPPytelVPorta-EtessamJMatias-GuiuJAPotential COVID-19 infection in patients with severe" exact="multiple sclerosis" post="treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating multiple sclerosis"/>
   <result pre="severe multiple sclerosis treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating" exact="multiple sclerosis" post="and neuromyelitis optica spectrum disorder during the COVID-19 pandemicNeurology2020942294995232241953"/>
   <result pre="treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating multiple sclerosis and" exact="neuromyelitis optica" post="spectrum disorder during the COVID-19 pandemicNeurology2020942294995232241953 91.https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-/116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf. Accessed 10"/>
   <result pre="Safety Communication. FDA warns about rare but serious risks of" exact="stroke" post="and blood vessel wall tears with multiple sclerosis drug"/>
   <result pre="serious risks of stroke and blood vessel wall tears with" exact="multiple sclerosis" post="drug Lemtrada (alemtuzumab). https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 10 July 2020. 94.OxleyTJMoccoJMajidiSet"/>
   <result pre="drug Lemtrada (alemtuzumab). https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 10 July 2020. 94.OxleyTJMoccoJMajidiSet al.Large-vessel" exact="stroke" post="as a presenting feature of Covid-19 in the youngN"/>
   <result pre="Neurol Disord201912175628641985498631244898 99.Dalla CostaGLeocaniLMontalbanXet al.Real-time assessment of COVID-19 prevalence among" exact="multiple sclerosis" post="patients: a multicenter European studyNeurol Sci202032617741 100.SormaniMPItalian Study Group"/>
   <result pre="European studyNeurol Sci202032617741 100.SormaniMPItalian Study Group on COVID-19 infection in" exact="multiple sclerosis." post="An Italian programme for COVID-19 infection in multiple sclerosis"/>
   <result pre="in multiple sclerosis. An Italian programme for COVID-19 infection in" exact="multiple sclerosis" post="[published correction appears in Lancet Neurol. 2020 May 28]Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7419263/results/search/disease/results.xml">
   <result pre="Bacillus Calmette-Guérin (BCG) vaccination program is the principal element of" exact="tuberculosis" post="control in Japan. We investigated the impact of routine"/>
   <result pre="on January 15, 2020.1 Because of an explosive increase in" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infections since late March, the Japanese"/>
   <result pre="The BCG vaccination program has been the principal element in" exact="tuberculosis" post="control in Japan for more than 70 years. Here,"/>
   <result pre="In 2004, in accordance with the national policy on improving" exact="tuberculosis" post="prevention and change in the target age of vaccination,"/>
   <result pre="Japan, routine BCG vaccination has been the principal element in" exact="tuberculosis" post="control. The incidence of tuberculosis in Japan has drastically"/>
   <result pre="been the principal element in tuberculosis control. The incidence of" exact="tuberculosis" post="in Japan has drastically decreased from 698.4 in 1951"/>
   <result pre="introduction of BCG to the country in 1924, data on" exact="tuberculosis" post="prevention and adverse event profiles had been accumulated mainly"/>
   <result pre="skin test screening.14 In 1999, a state of emergency concerning" exact="tuberculosis" post="was declared because gradual mitigation of tuberculosis prevention measures"/>
   <result pre="of emergency concerning tuberculosis was declared because gradual mitigation of" exact="tuberculosis" post="prevention measures during previous periods brought about a resurgence"/>
   <result pre="late 1990s and early 2000s, before establishment of the reinforced" exact="tuberculosis" post="control system, have relatively low BCG vaccine coverage. It"/>
   <result pre="antigensJ Infect Dis21720181798180829415180 13KatsudaN.HirosawaT.ReyerJ.A.HamajimaNRoles of public health centers (hokenjo) in" exact="tuberculosis" post="control in JapanNagoya J Med Sci772015192825797967 14Toida I.History of"/>
   <result pre="Sci772015192825797967 14Toida I.History of BCG vaccination. Information and review of" exact="tuberculosis" post="and respiratory disease research. 2004;48:15–40. Japanese. 15ObayashiYDried BCG vaccine1955World"/>
   <result pre="I.History of BCG vaccination. Information and review of tuberculosis and" exact="respiratory disease" post="research. 2004;48:15–40. Japanese. 15ObayashiYDried BCG vaccine1955World Health Organization MonographGenevaSeries"/>
   <result pre="16ObayashiY.ShimaoT.EbinaT.Comparison among various multi-puncture BCG vaccination methodsKekkaku391964369370Japanese 17RahmanM.TakahashiO.GotoM.FukuiTBCG vaccination and" exact="tuberculosis" post="in JapanJ Epidemiol13200312713512749599 18Declaration of State of Emergency Concerning"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7423333/results/search/disease/results.xml">
   <result pre="were more likely to accept the vaccine. When comparing reported" exact="influenza" post="vaccine uptake to reported acceptance of the COVID-19 vaccine:"/>
   <result pre="who did not complete high school had a very low" exact="influenza" post="vaccine uptake (10%), while 60% of the same group"/>
   <result pre="would accept the COVID-19 vaccine; 2) unemployed participants reported lower" exact="influenza" post="uptake and lower COVID-19 vaccine acceptance when compared to"/>
   <result pre="those employed or retired; and, 3) Black Americans reported lower" exact="influenza" post="vaccine uptake and lower COVID-19 vaccine acceptance than all"/>
   <result pre="vaccinated soon after the vaccine is available. Experience from the" exact="influenza" post="vaccines and others shows that vaccine uptake is not"/>
   <result pre="in vaccine intent for COVID-19 with no relationship with the" exact="influenza" post="vaccine. We also developed a predictive model to predict"/>
   <result pre="introduced. The U.S. already struggles with reaching high rates of" exact="influenza" post="vaccine coverage—with less than half of the adult population"/>
   <result pre="We also asked the participants if they had received the" exact="influenza" post="vaccine in the previous 8 months. Finally, participants were"/>
   <result pre="the frequency and percentage of COVID-19 vaccine acceptance and reported" exact="influenza" post="vaccination status were calculated. A chi-square analysis was completed"/>
   <result pre="calculated. A chi-square analysis was completed to compare the reported" exact="influenza" post="uptake to the reported COVID-19 vaccine acceptance. We calculated"/>
   <result pre="U.S. map. Similarly, we calculated and mapped the percentage for" exact="influenza" post="vaccine uptake by the ten DHHS regions. The 10"/>
   <result pre="of the percent of the sample who reported receiving the" exact="influenza" post="vaccine to those would reported they would accept the"/>
   <result pre="years. Vaccine acceptance for COVID-19 also differed compared to the" exact="influenza" post="vaccine with 348 (52%) of the participants having received"/>
   <result pre="vaccine with 348 (52%) of the participants having received the" exact="influenza" post="vaccine in the last eight months (chi-square p-value &amp;lt;"/>
   <result pre="0·01; Fig. 2). Notable demographic differences exist when comparing reported" exact="influenza" post="vaccine uptake to reported acceptance of the COVID-19 vaccine."/>
   <result pre="who did not complete high school, had a very low" exact="influenza" post="vaccine uptake (n = 1; 10%), but of that"/>
   <result pre="part of the sample that reported being unemployed reported lower" exact="influenza" post="uptake and lower COVID-19 vaccine acceptance when compared to"/>
   <result pre="reported being employed or retired. Additionally, Black Americans reported lower" exact="influenza" post="vaccine uptake (n = 28; 42%) and lower COVID-19"/>
   <result pre="A final demographic difference is that older adults reported higher" exact="influenza" post="vaccine uptake (n = 177; 69%) and higher COVID-19"/>
   <result pre="(Fig. 3 a). DHHS Region 8-Denver also had a higher" exact="influenza" post="vaccine coverage with over 75% (N = 20; n"/>
   <result pre="4 shows the percent COVID-19 vaccine acceptance against the percent" exact="influenza" post="vaccine coverage by state. There was no statistical association"/>
   <result pre="was no statistical association between COVID-19 vaccine acceptance and reported" exact="influenza" post="coverage (coefficient: 0·19; 95% CI: (-)0·19–0·57). Fig. 3 Comparison"/>
   <result pre="Fig. 3 Comparison of COVID-19 vaccine acceptance (A) to reported" exact="influenza" post="vaccine uptake (B) in the U.S. by Department of"/>
   <result pre="the% acceptance of COVID-19 vaccine plotted against the% coverage for" exact="influenza" post="vaccine by state. The solid line is the line"/>
   <result pre="found that Black Americans were less likely to get the" exact="influenza" post="vaccine and are less likely to accept a potential"/>
   <result pre="may amplify outbreaks [20,21] like it did during the 2019" exact="measles" post="outbreak. [22] Opposition to vaccines, which occurs actively online,"/>
   <result pre="were true (e.g., whether the participants had really received an" exact="influenza" post="vaccine is unknown). Another limitation is the effects of"/>
   <result pre="and Deaths in the United States - 2018 - 2019" exact="influenza" post="season. 2020. https://www.cdc.gov/flu/about/burden/2018-2019.html(accessed: 18th May 2020). 6LitmanL.RobinsonJ.AbberbockTCloudResearch.com: a versatile"/>
   <result pre="COVID-19 can fuel the spread of misinformationNature580202030632231320 22BeneckeO.DeYoungS.E.Anti-vaccine decision-making and" exact="measles" post="resurgence in the United StatesGlob Pediatr Health620192333794x19862949 23JohnsonN.F.VelasquezN.RestrepoN.J.The online"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7423510/results/search/disease/results.xml">
   <result pre="et al., 2020). The symptoms include fever, dry cough, fatigue," exact="shortness" post="of breath, chills, muscles pain, headache, gastric disturbances and"/>
   <result pre="due to prior exposure, reducing the efficacy. •May lead to" exact="cancer" post="due to the integration of the viral genome into"/>
   <result pre="FluGen | Bharat Biotech) M2SR, a self-limiting version of the" exact="influenza" post="virus, which is modified by insertion of the SARS-CoV-2"/>
   <result pre="protein. Furthermore, the vaccine expresses the hemagglutinin protein of the" exact="influenza" post="virus, thereby inducing immune response against both the viruses."/>
   <result pre="cells. It is potentially more immunogenic than the wild type" exact="influenza" post="virus and can be administered as a nasal spray"/>
   <result pre="antagonist, NS1, which is potentially more immunogenic than the wild-type" exact="influenza" post="virus.&quot; 10 CoroFlu, self-limiting influenza virus (M2SR)Non-replicating Viral Vector/"/>
   <result pre="more immunogenic than the wild-type influenza virus.&quot; 10 CoroFlu, self-limiting" exact="influenza" post="virus (M2SR)Non-replicating Viral Vector/ (Anon, 2020e; Anon, 2020c) University"/>
   <result pre="be administered via the nasal route. 11 Replicating viral vector/" exact="measles" post="vector/West Nile, CHIKV, Ebola, Lassa, Zika, MERS/ (Campbell, 2020;"/>
   <result pre="(Campbell, 2020; Anon, 2020c) The Institut Pasteur Pre-Clinical The proprietary" exact="measles" post="vector (MV) technology is chosen to develop the vaccine"/>
   <result pre="to protect against other infectious agents. 3 Live attenuated recombinant" exact="measles" post="virus (rMV)/ (Anon, 2020s; Anon, cc; Anon, 2020t) ZydusCadila"/>
   <result pre="developers. They are working on DNA vaccines, live attenuated recombinant" exact="measles" post="vaccines, inactivated viral vaccines, subunit vaccines, and the vaccines"/>
   <result pre="AhnJ.Y.SohnY.LeeS.H.Use of convalescent plasma therapy in two covid‐19 patients with" exact="acute respiratory distress syndrome" post="in KoreaJ Korean Med Sci.202010.3346/jkms.2020.35.e149 AnonCountries where COVID-19 has"/>
   <result pre="DoremalenNeeltje vanLambeTeresaSpencerAlexandraBelij-RammerstorferSandraPurushothamJyothi N.PortJulia R.AvanzatoVictoriaBushmakerTrentonFlaxmanAmyUlaszewskaMartaFeldmannFriederikeAllenElizabeth R.SharpeHannahJonathan ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaquess.l. : bioRxiv202010.1101/2020.05.13.093195 DorpLucy vanAcmanMislavRichardDamienShawLiam P.FordCharlotte E.OrmondLouiseOwenChristopher"/>
   <result pre="— Preliminary ReportN Engl J Med.July2020 JiangS.DuL.ShiZ.An emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: calling for developing therapeutic and"/>
   <result pre="with SARS-CoVNat Commun162020201110.1038/s41467-020-15562-9 ParkSu EunEpidemiology, virology, and clinical features of" exact="severe acute respiratory syndrome" post="-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)Clin Exp Pediatr202011912410.3345/cep.2020.0049332252141 Pharmaceutical Targeting the"/>
   <result pre="the Future2018[Online] October 11, 2018. https://www.infectioncontroltoday.com/public-health/100-years-after-spanish-flu-lessons-learned-and-challenges-futurehttps://www.infectioncontroltoday.com/ ShangW.YangY.RaoY.The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesNPJ Vaccines202010.1038/s41541-020-0170-0 ShenChenguangTreatment of 5 Critically"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7431109/results/search/disease/results.xml">
   <result pre="Epidemiol20203532533010.1007/s10654-020-00634-332318915 3.Schaffer DeRooSPudalovNJFuLYPlanning for a COVID-19 vaccination programJAMA202010.1001/jama.2020.871132421155 4.SchmidPRauberDBetschCLidoltGDenkerM-LBarriers of" exact="influenza" post="vaccination intention and behavior—a systematic review of influenza vaccine"/>
   <result pre="4.SchmidPRauberDBetschCLidoltGDenkerM-LBarriers of influenza vaccination intention and behavior—a systematic review of" exact="influenza" post="vaccine hesitancy, 2005–2016PLoS ONE201712e017055010.1371/journal.pone.017055028125629 5.PaakkariLOkanOCOVID-19: health literacy is an"/>
   <result pre="underestimated problemLancet Public Health20205e249e25010.1016/S2468-2667(20)30086-432302535 6.SancheSLinYTXuCRomero-SeversonEHengartnerNKeRHigh contagiousness and rapid spread of" exact="severe acute respiratory syndrome" post="coronavirus 2Emerg Infect Dis2020261470147710.3201/eid2607.20028232255761 7.Ministero della Salute. Dati coperture"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7431281/results/search/disease/results.xml">
   <result pre="The whole world is currently facing a pandemic of an" exact="infectious disease" post="known as novel coronavirus disease-2019 (COVID-19) caused by severe"/>
   <result pre="infectious disease known as novel coronavirus disease-2019 (COVID-19) caused by" exact="severe acute respiratory syndrome" post="coronavirus-2 (SARS-CoV-2) . This outbreak emerged unexpectedly and imposed"/>
   <result pre="decades, three coronavirus (CoV) outbreaks occurred in the world [1]:" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) in 2002 [2, 3], Middle East respiratory"/>
   <result pre="droplets. The manifestation of SARS-CoV-2 infections ranges from fever, cough," exact="shortness" post="of breath, fatigue, and, in a small population of"/>
   <result pre="of patients, gastrointestinal infection symptoms to acute respiratory distress and" exact="pneumonia" post="[15–17]. The loss of taste (ageusia) and loss of"/>
   <result pre="and the elderly people with underlying complications such as diabetes," exact="heart disease," post="lung disease, cancer, etc. are more susceptible to severe"/>
   <result pre="elderly people with underlying complications such as diabetes, heart disease," exact="lung disease," post="cancer, etc. are more susceptible to severe infection and"/>
   <result pre="China 80 Endovascular Thrombectomy in COVID-19 Infected Patients Completed Ischemic" exact="stroke" post="COVID-19 Other: mechanical trombectomy • Uhmontpellier, Montpellier, France 81"/>
   <result pre="Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Recruiting COVID-19" exact="pneumonia" post="Drug: plasma from COVID-19 convalescent patient Drug: human immunoglobulin"/>
   <result pre="COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic Recruiting COVID-19 interstitial" exact="pneumonia" post="• IRCCS Policlinico San Donato, San Donato Milanese, MI,"/>
   <result pre="treat malaria, as well as to treat the autoimmune diseases" exact="rheumatoid arthritis" post="and lupus [44–48]. Some preliminary reports have suggested that"/>
   <result pre="malaria, as well as to treat the autoimmune diseases rheumatoid" exact="arthritis" post="and lupus [44–48]. Some preliminary reports have suggested that"/>
   <result pre="alleged misconduct, hope, hype, and politicization that surrounds hydroxychloroquine, the" exact="malaria" post="drug touted as a COVID-19 treatment, a scientific picture"/>
   <result pre="3 mRNA Zydus Cadila ZyCoV-D vaccine Phase 1/2 RNA recombinant" exact="measles" post="virus Mudoch Childre’s Research Institute BCG vaccine Phase 2/3"/>
   <result pre="of concern to note that in COVID-19 patients succumbing to" exact="heart attack," post="IL-6 prevented the activity of STAT-5 signal transducer, thereby"/>
   <result pre="of Oxford. ChAdOx1 nCoV-19 has been genetically engineered using weakened" exact="common cold" post="adenovirus (ChAdOx1) infective only to chimpanzees. Genes coding for"/>
   <result pre="the AXL kinase protein and was originally developed to prevent" exact="cancer" post="cell metastasis. It has been proposed to use this"/>
   <result pre="so they do not prove very effective. Examples are flu," exact="hepatitis" post="A, etc. Attenuated Virus Vaccine Such viruses are more"/>
   <result pre="effects post-treatment. Some of the examples are rotavirus, measles, mumps," exact="rubella" post="(MMR combined vaccine), smallpox, etc. Thus, both live and"/>
   <result pre="4.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182023075143 5.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXClinical features of"/>
   <result pre="6.collab: World Health OrganizationWHO guidelines for the global surveillance of" exact="severe acute respiratory syndrome" post="(SARS): updated recommendations, October 20042004GenevaWorld Health Organization 7.MeoSAAlhowikanAMAl-KhlaiwiTMeoIMHalepotoDMIqbalMUsmaniAMHajjarWAhmedNNovel coronavirus"/>
   <result pre="the statusMilitary Med Res20207111 10.ChanJF-WYuanSKokK-Hcollab: To KK-WChuHYangJXingFLiuJYipCC-YPoonRW-SA familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 30.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXSmithECCaseJBFengJYJordanRCoronavirus susceptibility to the"/>
   <result pre="the proofreading exoribonucleasemBio201892e00221-0021829511076 31.RenLLWangYMWuZQXiangZCGuoLXuTJiangYZXiongYLiYJLiXWLiHFanGHGuXYXiaoYGaoHXuJYYangFWangXMWuCChenLLiuYWLiuBYangJWangXRDongJLiLHuangCLZhaoJPHuYChengZSLiuLLQianZHQinCJinQCaoBWangJWIdentification of a novel coronavirus causing severe" exact="pneumonia" post="in human: a descriptive studyChin Med J20201331015102432004165 32.LuRZhaoXLiJNiuPYangBWuHWangWSongHHuangBZhuNBiYMaXZhanFWangLHuTZhouHHuZZhouWZhaoLChenJMengYWangJLinYYuanJXieZMaJLiuWJWangDXuWHolmesECGaoGFWuGChenWShiWTanWGenomic characterisation"/>
   <result pre="and pharmacological properties of hydroxychloroquine and chloroquine in treatment of" exact="systemic lupus erythematosus," post="rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines"/>
   <result pre="pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic" exact="lupus erythematosus," post="rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines"/>
   <result pre="of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus," exact="rheumatoid arthritis" post="and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic"/>
   <result pre="hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid" exact="arthritis" post="and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic"/>
   <result pre="rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in" exact="systemic lupus erythematosus" post="and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin"/>
   <result pre="arthritis and related diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic" exact="lupus erythematosus" post="and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin"/>
   <result pre="diseasesInflammopharmacology201523523126926246395 45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and" exact="rheumatoid arthritis" post="patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin Rev Allergy Immunol201242214515321221847"/>
   <result pre="45.JCDSMarizHALFdRJPSSdODantasATALBPDIdRPGaldinoSLMGdRPHydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid" exact="arthritis" post="patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin Rev Allergy Immunol201242214515321221847"/>
   <result pre="in systemic lupus erythematosus and rheumatoid arthritis patientsClinics201368676677123778483 46.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from" exact="malaria" post="to autoimmunityClin Rev Allergy Immunol201242214515321221847 47.GladmanDDUrowitzMBSenecalJLFortinPJPettyREEsdaileJMCarretteSEdworthySMSmithCDThorneJCAspects of use of"/>
   <result pre="of optimized dosing design of hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis20207173273932150618 51.Gautret P, Lagier JC,"/>
   <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCR. J Korean Med Sci 35(6)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7431317/results/search/disease/results.xml">
   <result pre="Eradication Initiative (GPEI) was built on the wisdom gained from" exact="smallpox" post="eradication programs [1]. In 1980s, polio used to cause"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7435296/results/search/disease/results.xml">
   <result pre="Trial Study Team. Safety and efficacy of MVA85A, a new" exact="tuberculosis" post="vaccine, in infants previously vaccinated with BCG: a randomised,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7436383/results/search/disease/results.xml">
   <result pre="COVID‐19 due to the potential for progression to cytokine storm," exact="acute respiratory distress syndrome" post="and death as a result of NLRP3 inflammasome activation"/>
   <result pre="overall safety issues independent of vaccine type from studies in" exact="rheumatoid arthritis," post="systemic lupus erythematosus, spondyloarthropathy and primary systemic sclerosis.9 These"/>
   <result pre="issues independent of vaccine type from studies in rheumatoid arthritis," exact="systemic lupus erythematosus," post="spondyloarthropathy and primary systemic sclerosis.9 These conditions more closely"/>
   <result pre="independent of vaccine type from studies in rheumatoid arthritis, systemic" exact="lupus erythematosus," post="spondyloarthropathy and primary systemic sclerosis.9 These conditions more closely"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7437565/results/search/disease/results.xml">
   <result pre="doi: 10.1016/j.vaccine.2020.08.024 : Letter to the Editor The impact of" exact="influenza" post="vaccination on the COVID-19 pandemic? Evidence and lessons for"/>
   <result pre="so in the scientific community) regarding an alleged association between" exact="influenza" post="vaccination and coronavirus infection, mostly based on the study"/>
   <result pre="artfully manipulated by the anti-vaxxer community as an argument against" exact="influenza" post="vaccination. As pointed out by GG Wolff himself in"/>
   <result pre="or less (parainfluenza and respiratory syncytial virus) often detected among" exact="influenza" post="vaccinees. These results remain largely unexplained, could have age"/>
   <result pre="not concern the Sars-Cov-2 virus. There is extensive evidence that" exact="influenza" post="vaccination provides both health and economic benefits and it"/>
   <result pre="a number of papers that highlight the significant benefits of" exact="influenza" post="vaccination in the current COVID-19 pandemic. Skowronski et al."/>
   <result pre="and found (at odds with Wolff’s findings) no effect of" exact="influenza" post="vaccination on the risk of coronaviruses infection [3]. An"/>
   <result pre="the risk of coronaviruses infection [3]. An inverse correlation between" exact="influenza" post="vaccine coverage and COVID-19 mortality emerged in an ecological"/>
   <result pre="developed and validated a COVID-19 infection prediction model, in which" exact="influenza" post="vaccinees had a reduced COVID-19 infection risk [5]. Finally,"/>
   <result pre="a modelling paper by Li et al. concluded that &quot;increasing" exact="influenza" post="vaccine uptake […] would facilitate the management of respiratory"/>
   <result pre="use of healthcare resources [6]. In conclusion, we recommend that" exact="influenza" post="vaccination continues to be promoted as a central public"/>
   <result pre="avoiding an overload of health services and hospitals associated with" exact="influenza" post="infections. In addition, influenza vaccination plays an important role"/>
   <result pre="health services and hospitals associated with influenza infections. In addition," exact="influenza" post="vaccination plays an important role in protecting the elderly,"/>
   <result pre="a public health perspective we think it is important that" exact="influenza" post="vaccination programmes are continued during the upcoming winter seasons."/>
   <result pre="Raina MacIntyre has received funding from Sanofi and Seqirus for" exact="influenza" post="research in the past five years and has been"/>
   <result pre="virus interference among Department of Defense personnel during the 2017–2018" exact="influenza" post="seasonVaccine.382202035035431607599 2WolffG.G.Letter to the EditorVaccine38302020465132471778 3Skowronski DM, Zou M,"/>
   <result pre="10.1016/j.chest.2020.05.580. Epub ahead of print. 6LiQ.TangB.BragazziN.L.XiaoY.WuJ.Modeling the impact of mass" exact="influenza" post="vaccination and public health interventions on COVID-19 epidemics with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7440153/results/search/disease/results.xml">
   <result pre="pandemic on March 11, 2020 [1]. COVID-19 is caused by" exact="severe acute respiratory syndrome" post="coronavirus-2 (SARS-CoV-2), with cases ranging from individuals who are"/>
   <result pre="examining people’s acceptability of a COVID-19 vaccine. During the 2009" exact="influenza" post="A (H1N1) pandemic, early estimates of vaccine acceptability suggested"/>
   <result pre="adults in the US intended to get the 2009 H1N1" exact="influenza" post="vaccine [7], [8], [9]. However, little is currently known"/>
   <result pre="them at higher risk for severe illness from COVID-19 (chronic" exact="lung disease," post="asthma, serious heart conditions, being immunocompromised, diabetes, chronic kidney"/>
   <result pre="(chronic lung disease, asthma, serious heart conditions, being immunocompromised, diabetes," exact="chronic kidney disease," post="liver disease, or body mass index of 40 or"/>
   <result pre="asthma, serious heart conditions, being immunocompromised, diabetes, chronic kidney disease," exact="liver disease," post="or body mass index of 40 or higher) [16]."/>
   <result pre="the H1N1 pandemicAm J Public Health.1024201267267922397349 8MaurerJ.HarrisK.M.ParkerA.LurieN.Does receipt of seasonal" exact="influenza" post="vaccine predict intention to receive novel H1N1 vaccine: Evidence"/>
   <result pre="nationally representative survey of U.S. adultsVaccine.274220095732573419679219 9HorneyJ.A.MooreZ.DavisM.MacDonaldP.D.Intent to receive pandemic" exact="influenza" post="A (H1N1) vaccine, compliance with social distancing and sources"/>
   <result pre="adolescent daughtersSoc Sci Med.693200947548019540642 31LingM.KotheE.J.MullanB.A.Predicting intention to receive a seasonal" exact="influenza" post="vaccination using protection motivation theorySoc Sci Med.2332019879231195194 32GarganoL.M.HerbertN.L.PainterJ.E.Development, theoretical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7443330/results/search/disease/results.xml">
   <result pre="province of China became the center of an outbreak of" exact="pneumonia" post="of unknown cause, which raised intense attention not only"/>
   <result pre="February 11, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20,200,211-sitrep-22-ncov.pdf. Accessed May27, 2020.,&quot; n.d.). COVID-19, a" exact="respiratory disease," post="has led to more than 22,140,472 confirmed cases and"/>
   <result pre="November 2002, when an infectious agent caused outbreaks of atypical" exact="pneumonia" post="in Guangdong Province, southern China, and Southeast Asia, North"/>
   <result pre="and countries. The disease caused by the virus was named" exact="severe acute respiratory syndrome" post="(SARS), for which a global alert was issued by"/>
   <result pre="The coronavirus was first identified as a cause of the" exact="common cold" post="in 1960 (Al-Osail and Al-Wazzah, 2017). Coronaviruses belong to"/>
   <result pre="Alphacoronaviruses and betacoronaviruses usually cause respiratory illness in humans and" exact="gastroenteritis" post="in animals. These two families include seven strains of"/>
   <result pre="pharyngitis, sinusitis, and other systemic symptoms such as occasional watery" exact="diarrhea" post="in humans of all ages. Based on current sequence"/>
   <result pre="receptor (Li et al., 2003; Raj et al., 2013). Murine" exact="hepatitis" post="virus (MHV), a β-coronavirus, uses carcinoembryonic antigen-related cell adhesion"/>
   <result pre="of aminopeptidase N (APN) (Godet et al., 1994), whereas transmissible" exact="gastroenteritis" post="virus (TGEV) requires recognition of APN in addition to"/>
   <result pre="to induce anti-tumor responses. GRP78, CD38, and GPC3 expression on" exact="cancer" post="cells have also been targeted for nanobody expression and"/>
   <result pre="been targeted for nanobody expression and purification, which provide useful" exact="cancer" post="cell markers and potential therapeutic markers (Aghamollaei et al.,"/>
   <result pre="from HIV (Forthal et al., 2001; Haynes et al., 2012)," exact="herpes simplex" post="virus (Kohl et al., 2000; Kohl and Loo, 1982,"/>
   <result pre="virus (Gunn et al., 2018; Saphire et al., 2018), and" exact="influenza" post="virus (Greenberg et al., 1977; Jegaskanda et al., 2014),"/>
   <result pre="approved a bivalent nanobody, caplacizumab, for treatment of patients with" exact="thrombotic thrombocytopenic purpura" post="(Hanlon and Metjian, 2020; Scully et al., 2019). Several"/>
   <result pre="bivalent nanobody, caplacizumab, for treatment of patients with thrombotic thrombocytopenic" exact="purpura" post="(Hanlon and Metjian, 2020; Scully et al., 2019). Several"/>
   <result pre="Nanobodies have also exhibited good antiviral effects against bovine viral" exact="diarrhea" post="virus (Li et al., 2017). Only limited studies have"/>
   <result pre="in the generation of vaccine candidates against SARS-CoV. Also, a" exact="rabies" post="virus-based vaccine expressing the SARS-CoV S protein has been"/>
   <result pre="Cadila Codon-optimised proteins of the new coronavirus, expressed by replicating" exact="measles" post="viral vector, will use reverse genetics to stimulate long-term"/>
   <result pre="for Vaccine Research The vaccine candidate consists of a replicating" exact="measles" post="viral vector Pre-Clinical (&quot;CEPI. CEPI collaborates with the Institut"/>
   <result pre="BiOCAD and IEM This viral vector vaccine based on attenuated" exact="influenza" post="virus backbone (intranasal) Pre-Clinical (&quot;BIOCAD, 2020. https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/. Accessed May21,"/>
   <result pre="The new intranasal vaccine is based on NasoVAX, the company’s" exact="influenza" post="vaccine candidate. Like NasoVAX, single intranasal dose would provide"/>
   <result pre="and Houser et al. (2017). References References AdedejiA.O.SeversonW.JonssonC.SinghK.WeissS.R.SarafianosS.G.Novel inhibitors of" exact="severe acute respiratory syndrome" post="coronavirus entry that act by three distinct mechanismsJ. Virol.8720138017802810.1128/JVI.00998-1323678171"/>
   <result pre="characterization of a novel nanobody for detection of GRP78 expressing" exact="cancer" post="cellsBiotechnol. Appl. Biochem.202010.1002/bab.1916 AJ VaccinesAJ Vaccines to Develop Vaccine"/>
   <result pre="is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from" exact="severe acute respiratory syndrome" post="coronavirus 2 with high potencyJ. Biol. Chem. jbc.RA120.013679.202010.1074/jbc.RA120.013679 CaoY.DengQ.DaiS.Remdesivir"/>
   <result pre="coronavirus 2 with high potencyJ. Biol. Chem. jbc.RA120.013679.202010.1074/jbc.RA120.013679 CaoY.DengQ.DaiS.Remdesivir for" exact="severe acute respiratory syndrome" post="coronavirus 2 causing COVID-19: an evaluation of the evidenceTravel"/>
   <result pre="March 19https://cepi.net/news_cepi/cepi-collaborates-withthe-2020institut-pasteur-in-a-consortium-to-develop-covid-19- vaccine/. Accessed May 21, 2020., n.d ChenZ.ZhangL.QinC.BaL.YiC.E.ZhangF.WeiQ.HeT.YuW.YuJ.GaoH.TuX.GettieA.FarzanM.YuenK.-Y.HoD.D.Recombinant modified" exact="vaccinia virus" post="Ankara expressing the spike glycoprotein of severe acute respiratory"/>
   <result pre="ChenZ.ZhangL.QinC.BaL.YiC.E.ZhangF.WeiQ.HeT.YuW.YuJ.GaoH.TuX.GettieA.FarzanM.YuenK.-Y.HoD.D.Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of" exact="severe acute respiratory syndrome" post="coronavirus induces protective neutralizing antibodies primarily targeting the receptor"/>
   <result pre="Microbes Infect.720186010.1038/s41426-018-0056-729618723 DuL.HeY.WangY.ZhangH.MaS.WongC.K.L.WuS.H.W.NgF.HuangJ.-D.YuenK.-Y.JiangS.ZhouY.ZhengB.-J.Recombinant adeno-associated virus expressing the receptor-binding domain of" exact="severe acute respiratory syndrome" post="coronavirus S protein elicits neutralizing antibodies: Implication for developing"/>
   <result pre="One82013e8158710.1371/journal.pone.0081587 DuanH.MaZ.XuL.ZhangA.LiZ.XiaoS.A novel intracellularly expressed NS5B-specific nanobody suppresses bovine viral" exact="diarrhea" post="virus replicationVet. Microbiol.240202010844910.1016/j.vetmic.2019.108449 DvekslerG.S.PensieroM.N.CardellichioC.B.WilliamsR.K.JiangG.S.HolmesK.V.DieffenbachC.W.Cloning of the mouse hepatitis virus"/>
   <result pre="bovine viral diarrhea virus replicationVet. Microbiol.240202010844910.1016/j.vetmic.2019.108449 DvekslerG.S.PensieroM.N.CardellichioC.B.WilliamsR.K.JiangG.S.HolmesK.V.DieffenbachC.W.Cloning of the mouse" exact="hepatitis" post="virus (MHV) receptor: expression in human and hamster cell"/>
   <result pre="May 21, 2020., n.d WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.YuanM.-L.ZhangY.-L.DaiF.-H.LiuY.WangQ.-M.ZhengJ.-J.XuL.HolmesE.C.ZhangY.-Z.A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature579202026526910.1038/s41586-020-2008-332015508 FaberM.LamirandeE.W.RobertsA.RiceA.B.KoprowskiH.DietzscholdB.SchnellM.J.A single immunization with a rhabdovirus-based vector"/>
   <result pre="in ChinaNature579202026526910.1038/s41586-020-2008-332015508 FaberM.LamirandeE.W.RobertsA.RiceA.B.KoprowskiH.DietzscholdB.SchnellM.J.A single immunization with a rhabdovirus-based vector expressing" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) S protein results in the production of"/>
   <result pre="GeoVax-Progresses-in-Coronavirus-COVID-19-Vaccine-Development-Program.html. Accessed May21, 2020., n.d GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.SteffenI.TsegayeT.S.HeY.GnirssK.NiemeyerD.SchneiderH.DrostenC.PöhlmannS.Evidence that TMPRSS2 activates the" exact="severe acute respiratory syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
   <result pre="determinants are located within the same domain of the transmissible" exact="gastroenteritis" post="virus (coronavirus) spike proteinJ. Virol.681994800880167525985 GorlaniA.ForthalD.N.Antibody-dependent enhancement and the"/>
   <result pre="the risk of HIV infectionCurr. HIV Res.11201342142610.2174/1570162x11311666006224191936 GreenbergS.B.CriswellB.S.SixH.R.CouchR.B.Lymphocyte cytotoxicity to" exact="influenza" post="virus-infected cells. II. Requirement for antibody and non-T lymphocytesJ."/>
   <result pre="monoclonal antibody-mediated protection against ebola virusCell Host Microbe24201822123310.1016/j.chom.2018.07.009e530092199 HambachJ.RieckenK.CichutekS.SchützeK.AlbrechtB.PetryK.Targeting CD38-Expressing" exact="multiple myeloma" post="and burkitt lymphoma cells in vitro with nanobody-based chimeric"/>
   <result pre="ebola virusCell Host Microbe24201822123310.1016/j.chom.2018.07.009e530092199 HambachJ.RieckenK.CichutekS.SchützeK.AlbrechtB.PetryK.Targeting CD38-Expressing multiple myeloma and burkitt" exact="lymphoma" post="cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs)Cells9202010.3390/cells9020321"/>
   <result pre="antibodies in infected patientsJ. Virol.7820046134614210.1128/JVI.78.12.6134-6142.200415163706 HofmannH.PyrcK.HoekLvanderGeierM.BerkhoutB.PöhlmannS.Human coronavirus NL63 employs the" exact="severe acute respiratory syndrome" post="coronavirus receptor for cellular entryPNAS10220057988799310.1073/pnas.040946510215897467 HouserK.V.Enhanced inflammation in New"/>
   <result pre="and identification of linear B-cell epitopes and entry-blocking peptide of" exact="severe acute respiratory syndrome" post="(SARS)-associated coronavirus using synthetic overlapping peptide libraryJ. Comb. Chem.7200564865610.1021/cc050060716153058"/>
   <result pre="FcγR pathwayJ. Virol.852011105821059710.1128/JVI.00671-1121775467 JegaskandaS.ReadingP.C.KentS.J.Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal" exact="influenza" post="vaccineJ. Immunol.193201446947510.4049/jimmunol.140043224994909 JiL.DongC.FanR.QiS.A high affinity nanobody against endothelin receptor"/>
   <result pre="the treatment of melanomaMol. Biol. Rep.4720202137214710.1007/s11033-020-05313-w32080807 JiangS.DuL.ShiZ.An emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: calling for developing therapeutic and"/>
   <result pre="coronavirus vaccines: immunogenicity and rapid translational developmentEBioMedicine202010274310.1016/j.ebiom.2020.10274332249203 KobingerG.P.FigueredoJ.M.RoweT.ZhiY.GaoG.SanmiguelJ.C.BellP.WivelN.A.ZitzowL.A.FliederD.B.HoganR.J.WilsonJ.M.Adenovirus-based vaccine prevents" exact="pneumonia" post="in ferrets challenged with the SARS coronavirus and stimulates"/>
   <result pre="robust immune responses in macaquesVaccine2520075220523110.1016/j.vaccine.2007.04.06517559989 KohlS.LooL.S.Protection of neonatal mice against" exact="herpes simplex" post="virus infection: probable in vivo antibody-dependent cellular cytotoxicityJ. Immunol.12919823703766282968"/>
   <result pre="Immunol.12919823703766282968 KohlS.CharleboisE.D.SigouroudiniaM.GoldbeckC.HartogK.SekulovichR.E.LangenbergA.G.M.BurkeR.L.Limited antibody-dependent cellular cytotoxicity antibody response induced by a" exact="herpes simplex" post="virus type 2 subunit vaccineJ. Infect. Dis.181200033533910.1086/31520810608784 KorberB.FischerW.M.GnanakaranS.YoonH.TheilerJ.AbfaltererW.HengartnerN.GiorgiE.E.BhattacharyaT.FoleyB.HastieK.M.ParkerM.D.PartridgeD.G.EvansC.M.FreemanT.M.de SilvaT.I.McDanalC.PerezL.G.TangH.Moon-WalkerA.WhelanS.P.LaBrancheC.C.SaphireE.O.MontefioriD.C.AngyalA.BrownR.L.CarrileroL.GreenL.R.GrovesD.C.JohnsonK.J.KeeleyA.J.LindseyB.B.ParsonsP.J.RazaM.Rowland-JonesS.SmithN.TuckerR.M.WangD.WylesM.D.Tracking"/>
   <result pre="the sialic acid binding activity with the enteropathogenicity of transmissible" exact="gastroenteritis" post="coronavirusJ. Virol.711997328532879060696 XiaL.TengQ.ChenQ.ZhangF.Preparation and characterization of Anti-GPC3 nanobody against"/>
   <result pre="confirmed cases: estimation and applicationAnn. Intern. Med.202010.7326/M20-0504 LaursenN.S.FriesenR.H.E.ZhuX.JongeneelenM.BloklandS.VermondJ.Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutininScience362201859860210.1126/science.aaq062030385580 LedwithB.J.ManamS.TroiloP.J.BarnumA.B.PauleyC.J.GriffithsT.G.HarperL.B.SchockH.B.ZhangH.FarisJ.E.WayP.A.BeareC.M.BagdonW.J.NicholsW.W.Plasmid"/>
   <result pre="LaursenN.S.FriesenR.H.E.ZhuX.JongeneelenM.BloklandS.VermondJ.Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutininScience362201859860210.1126/science.aaq062030385580 LedwithB.J.ManamS.TroiloP.J.BarnumA.B.PauleyC.J.GriffithsT.G.HarperL.B.SchockH.B.ZhangH.FarisJ.E.WayP.A.BeareC.M.BagdonW.J.NicholsW.W.Plasmid DNA vaccines: assay for integration into host"/>
   <result pre="into host genomic DNADev. Biol. (Basel)1042000334311713822 LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.B.ToK.F.LuiS.F.SzetoC.C.ChungS.SungJ.J.Y.A major outbreak of" exact="severe acute respiratory syndrome" post="in Hong KongN. Engl. J. Med.34820031986199410.1056/NEJMoa03068512682352 LetkoM.MarziA.MunsterV.Functional assessment of"/>
   <result pre="coronavirusNature426200345045410.1038/nature0214514647384 LiT.HuangM.XiaoH.ZhangG.DingJ.WuP.ZhangH.ShengJ.ChenC.Selection and characterization of specific nanobody against bovine virus" exact="diarrhea" post="virus (BVDV) E2 proteinPLoS One122017e017846910.1371/journal.pone.0178469 LiS.ZhangW.JiangK.ShanH.ShiM.ChenB.HuaZ.Nanobody against the E7"/>
   <result pre="of coronavirusesAdvances in Virus Research2006Academic Press19329210.1016/S0065-3527(06)66005-3 MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the" exact="severe acute respiratory syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2J. Virol.842010126581266410.1128/JVI.01542-1020926566"/>
   <result pre="SARS-CoV-2 enhances spike protein cleavage by TMPRSSbioRxiv2020202010.1101/2020.02.08.92600602.08.926006 MeyerK.Ait-GoughoulteM.KeckZ.-Y.FoungS.RayR.Antibody-dependent enhancement of" exact="hepatitis" post="C virus infectionJ. Virol.8220082140214910.1128/JVI.01867-0718094180 MIGAL’s Coronavirus Vaccine Project:https://www.migal.org.il/en/node/7010. Accessed"/>
   <result pre="2020., n.d. SchriewerL.SchützeK.PetryK.HambachJ.FumeyW.KoenigsdorfJ.Nanobody-based CD38-specific heavy chain antibodies induce killing of" exact="multiple myeloma" post="and other hematological malignanciesTheranostics1020202645265810.7150/thno.3853332194826 SchultzeB.GrossH.J.BrossmerR.HerrlerG.The S protein of bovine"/>
   <result pre="2020., n.d ShullaA.Heald-SargentT.SubramanyaG.ZhaoJ.PerlmanS.GallagherT.A transmembrane serine protease is linked to the" exact="severe acute respiratory syndrome" post="coronavirus receptor and activates virus entryJ. Virol.85201187388210.1128/JVI.02062-1021068237 SiuY.L.TeohK.T.LoJ.ChanC.M.KienF.EscriouN.TsaoS.W.NichollsJ.M.AltmeyerR.PeirisJ.S.M.BruzzoneR.NalB.The M,"/>
   <result pre="genetic recombination, and pathogenesis of coronavirusesTrends Microbiol.24201649050210.1016/j.tim.2016.03.00327012512 SuiJ.LiW.MurakamiA.TaminA.MatthewsL.J.WongS.K.MooreM.J.TallaricoA.S.C.OlurindeM.ChoeH.AndersonL.J.BelliniW.J.FarzanM.MarascoW.A.Potent neutralization of" exact="severe acute respiratory syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
   <result pre="Marchhttp://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models2020Accessed on May 21, 2020., n.d TarrA.W.LafayeP.MeredithL.Damier-PiolleL.UrbanowiczR.A.MeolaA.JestinJ.-L.BrownR.J.P.McKeatingJ.A.ReyF.A.BallJ.K.KreyT.An alpaca nanobody inhibits" exact="hepatitis" post="C virus entry and cell-to-cell transmissionHepatology58201393293910.1002/hep.2643023553604 ter MeulenJ.BakkerA.B.H.van den"/>
   <result pre="neutralization of SARS coronavirusNat. Med.10200487187510.1038/nm108015247913 TsangK.W.HoP.L.OoiG.C.YeeW.K.WangT.Chan-YeungM.LamW.K.SetoW.H.YamL.Y.CheungT.M.WongP.C.LamB.IpM.S.ChanJ.YuenK.Y.LaiK.N.A cluster of cases of" exact="severe acute respiratory syndrome" post="in Hong KongN. Engl. J. Med.34820031977198510.1056/NEJMoa03066612671062 TseL.V.MeganckR.M.GrahamR.L.BaricR.S.The current and"/>
   <result pre="21, 2020., n.d van DoremalenN.LambeT.SpencerA.Belij-RammerstorferS.PurushothamJ.N.PortJ.R.AvanzatoV.BushmakerT.FlaxmanA.UlaszewskaM.FeldmannF.AllenE.R.SharpeH.SchulzJ.HolbrookM.OkumuraA.Meade-WhiteK.Pérez-PérezL.BissettC.GilbrideC.WilliamsonB.N.RosenkeR.LongD.IshwarbhaiA.KailathR.RoseL.MorrisS.PowersC.LovaglioJ.HanleyP.W.ScottD.SaturdayG.de WitE.GilbertS.C.MunsterV.J.ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaques (preprint)Microbiology.202010.1101/2020.05.13.093195 VaxartVaxart Announces Additional Positive Pre-clinical"/>
   <result pre="non-neutralising antibodies at early stages of infectionRetrovirology820111610.1186/1742-4690-8-1621401915 WilliamsR.K.JiangG.S.HolmesK.V.Receptor for mouse" exact="hepatitis" post="virus is a member of the carcinoembryonic antigen family"/>
   <result pre="protective efficacy against MERS-CoVJ. Virol.92201810.1128/JVI.00837-18e00837-18, /jvi/92/18/e00837-18.atom ZhongN.S.ZhengB.J.LiY.M.PoonL.L.M.XieZ.H.ChanK.H.LiP.H.TanS.Y.ChangQ.XieJ.P.LiuX.Q.XuJ.LiD.X.YuenK.Y.PeirisJ.S.M.GuanY.Epidemiology and cause of" exact="severe acute respiratory syndrome" post="(SARS) in Guangdong, People’s Republic of China, in February,"/>
   <result pre="in Guangdong, People’s Republic of China, in February, 2003Lancet36220031353135810.1016/S0140-6736(03)14630-214585636 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7443809/results/search/disease/results.xml">
   <result pre="from a large proportion of asymptomatic infections to fulminant pneumonia," exact="acute respiratory distress syndrome" post="(ARDS), multiple organ failure and death. Although SARS-CoV-2 infection"/>
   <result pre="now entered later stage human clinical trials. During the swine" exact="influenza" post="pandemic of 2009, the first vaccines were available within"/>
   <result pre="within 6 months in the Western world based on seasonal" exact="influenza" post="vaccine production. As there are no licensed CoV vaccines"/>
   <result pre="with severity of diseasemedRxiv202010.1101/2020.04.14.2006577132817980 2.ChanKHet al.Serological responses in patients with" exact="severe acute respiratory syndrome" post="coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7444935/results/search/disease/results.xml">
   <result pre="the current promising approaches for the development of an effective" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) vaccine MirzaeiRasoulrasul.micro92@gmail.comab⁎MohammadzadehRokhsarehcMahdaviFarzaddBadrzadehFaribaeKazemiSheidafEbrahimiMehdigSoltaniFatemehhKazemiSimaaJedaAli SalimiiDarvishmotevalliMohammadjYousefimashoufRasoulaKeyvaniHosseinkeyvani.h@iums.ac.iri⁎KarampoorSajadsajadkarampour1987@gmail.comi⁎[a], [b], [c], [d],"/>
   <result pre="several countries. Abstract Coronavirus disease 2019 (COVID-19) is a pandemic" exact="infectious disease" post="caused by the novel coronavirus called SARS-CoV-2. There is"/>
   <result pre="Corona virus disease 2019 (COVID-19), also known as 2019-nCoV acute" exact="respiratory disease," post="is caused by SARS-CoV-2 that has led the current"/>
   <result pre="respiratory tract system and causes symptoms similar to those of" exact="common cold," post="including respiratory disorders, runny nose, dry cough, dizziness, sore"/>
   <result pre="and elderly individuals, COVID-19 symptoms can become more severe, causing" exact="pneumonia" post="and bronchitis [8]. The case fatality rate of this"/>
   <result pre="cases, a cytokine storm has been observed that causes the" exact="acute respiratory distress syndrome" post="[21], [22], [23]. Other reports on severe COVID-19 cases"/>
   <result pre="an overview of SARS-CoV-2 candidate vaccines. 5 Candidate vaccines for" exact="severe acute respiratory syndrome" post="Several approaches have been considered for the development of"/>
   <result pre="the immunogenicity of these vaccines as the decreased severity of" exact="pneumonia" post="and viral titer were reported [45]. Subunit vaccines are"/>
   <result pre="been found that the deletion of nsp-1 gene in murine" exact="hepatitis" post="virus can be used for the development of a"/>
   <result pre="several viral infections such as HIV (human immunodeficiency virus), Ebola," exact="hepatitis" post="C, rabies, as well as SARS, and the results"/>
   <result pre="caused by MERS candidate vaccines such as Chimpanzee-adenovirus and modified" exact="vaccinia virus" post="Ankara (Modified Vaccinia Ankara) were investigated. These vaccines induced"/>
   <result pre="of coronaviruses infection initially raised from studies on feline infectious" exact="peritonitis" post="virus (FIPV) [84]. FIPV infects myeloid-derived cells, such as"/>
   <result pre="vaccines that provide low titers of neutralizing antibodies led to" exact="peritonitis" post="and higher mortality rates in kittens [86]. Concerns were"/>
   <result pre="a principal target for vaccine development. 9 Ongoing vaccines for" exact="severe acute respiratory syndrome" post="coronavirus 2 Vaccines for acute viral infections are developed"/>
   <result pre="more challenging in the elderly as low efficacy of seasonal" exact="influenza" post="vaccines has been observed in this population [113]. By"/>
   <result pre="A promising effect has been indicated against viral pathogens, including" exact="yellow fever," post="herpes simplex virus, respiratory syncytial virus, and human papillomavirus"/>
   <result pre="effect has been indicated against viral pathogens, including yellow fever," exact="herpes simplex" post="virus, respiratory syncytial virus, and human papillomavirus [119]. Due"/>
   <result pre="live attenuated vaccine comprised of the causative agent of bovine" exact="tuberculosis" post="(Mycobacterium bovis). Amazingly, BCG vaccination seems to not only"/>
   <result pre="vaccination seems to not only protect humans against severe childhood" exact="tuberculosis" post="but has non-specific protective effects against other respiratory tract"/>
   <result pre="overly susceptible to COVID-19. One hypothesis is that antibodies against" exact="measles" post="(due to the MMR vaccine) may be cross-reactive with"/>
   <result pre="combined with survivin. IMV is currently evaluating DPX-Survivac in advanced" exact="ovarian cancer," post="as well as in combination therapy in various clinical"/>
   <result pre="induce immunity against this virus. CoroFlu will also display the" exact="influenza" post="virus hemagglutinin protein, which is the dominant influenza virus"/>
   <result pre="display the influenza virus hemagglutinin protein, which is the dominant" exact="influenza" post="virus antigen, so that immune responses will be induced"/>
   <result pre="that immune responses will be induced against both coronavirus and" exact="influenza" post="(H2N2 seasonal flu strain). [154] 10 Adjuvants Vaccine candidates"/>
   <result pre="the S protein of SARS-CoV-2, protected rhesus monkeys from developing" exact="pneumonia" post="[127]. This vaccine significantly diminished the viral loads in"/>
   <result pre="trial for the MERS-CoV vaccine [127]. An MVA-MERS-S (MVA: modified" exact="vaccinia virus" post="Ankara) DNA vaccine was safe, well-tolerated, and produced humoral"/>
   <result pre="The CpG 1018 adjuvant has been used in an FDA-approved" exact="hepatitis" post="B vaccine (HEPLISAV-B®) [127]. GlaxoSmithKline has also teamed up"/>
   <result pre="similar to the means employed for their approved Flublok recombinant" exact="influenza" post="virus vaccine [138], Sanofi's vaccine is also months, if"/>
   <result pre="to make vaccines accessible to the global population. Even for" exact="influenza" post="virus vaccines, for which many production facilities exist in"/>
   <result pre="94(4) (2020). 20LeungD.T.M.Chi HangT.F.Chun HungM.Sheung ChanP.K.CheungJ.L.K.NiuH.TamJ.S.L.LimP.L.Antibody response of patients with" exact="severe acute respiratory syndrome" post="(SARS) targets the viral nucleocapsidJ. Infect. Dis.1902200437938615216476 21HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.Clinical features"/>
   <result pre="peripheral blood of 123 hospitalized patients with 2019 novel coronavirus" exact="pneumonia" post="(NCP)MedRxiv2020 25WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.Clinical characteristics of 138 hospitalized patients with 2019"/>
   <result pre="25WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, ChinaJama32311202010611069 26QinC.ZhouL.HuZ.ZhangS.YangS.TaoY.XieC.MaK.ShangK.WangW.Dysregulation of immune response in patients"/>
   <result pre="33Navas-MartínS.WeissS.R.Coronavirus replication and pathogenesis: implications for the recent outbreak of" exact="severe acute respiratory syndrome" post="(SARS), and the challenge for vaccine developmentJ. Neurovirol.1022004758515204926 34XiongS.WangY.-F.ZhangM.-Y.LiuX.-J.ZhangC.-H.LiuS.-S.QianC.-W.LiJ.-X.LuJ.-H.WanZ.-Y.Immunogenicity"/>
   <result pre="vaccine protective in miceEmerg. Infect. Dis.1182005131216110580 39SeeR.H.ZakhartchoukA.N.PetricM.LawrenceD.J.MokC.P.HoganR.J.RoweT.ZitzowL.A.KarunakaranK.P.HittM.M.Comparative evaluation of two" exact="severe acute respiratory syndrome" post="(SARS) vaccine candidates in mice challenged with SARS coronavirusJ."/>
   <result pre="40LinJ.ZhangJ.-S.SuN.XuJ.-G.WangN.ChenJ.-T.ChenX.LiuY.-X.GaoH.JiaY.-P.Safety and immunogenicity from a phase I trial of inactivated" exact="severe acute respiratory syndrome" post="coronavirus vaccineAntiviral Therapy1272007110718018769 41RochaC.D.CaetanoB.C.MachadoA.V.Bruña-RomeroO.Recombinant viruses as tools to induce"/>
   <result pre="Immunol.9419975175249287173 44ImlerJ.-L.Adenovirus vectors as recombinant viral vaccinesVaccine13131995114311518578797 45KobingerG.P.FigueredoJ.M.RoweT.ZhiY.GaoG.SanmiguelJ.C.BellP.WivelN.A.ZitzowL.A.FliederD.B.Adenovirus-based vaccine prevents" exact="pneumonia" post="in ferrets challenged with the SARS coronavirus and stimulates"/>
   <result pre="receptor for the SARS coronavirusNature4266965200345045414647384 50OlsenC.W.A review of feline infectious" exact="peritonitis" post="virus: molecular biology, immunopathogenesis, clinical aspects, and vaccinationVet. Microbiol.361–219931378236772"/>
   <result pre="biology, immunopathogenesis, clinical aspects, and vaccinationVet. Microbiol.361–219931378236772 51AntónI.M.GonzálezS.BullidoM.J.CorsínM.RiscoC.LangeveldJ.P.EnjuanesL.Cooperation between transmissible" exact="gastroenteritis" post="coronavirus (TGEV) structural proteins in the in vitro induction"/>
   <result pre="and characterization of DNA vaccines targeting the nucleocapsid protein of" exact="severe acute respiratory syndrome" post="coronavirusJ. Virol.78920044638464515078946 54WangX.XuW.TongD.NiJ.GaoH.WangY.ChuY.LiP.YangX.XiongS.A chimeric multi-epitope DNA vaccine elicited specific"/>
   <result pre="a SARS-CoV nucleocapsid protein geneCell Mol. Immunol.36200645946517257500 58LamirandeE.W.DeDiegoM.L.RobertsA.JacksonJ.P.AlvarezE.SheahanT.ShiehW.-J.ZakiS.R.BaricR.EnjuanesL.A live attenuated" exact="severe acute respiratory syndrome" post="coronavirus is immunogenic and efficacious in golden Syrian hamstersJ."/>
   <result pre="protect mice from MERS-CoV infectionVaccine351220171586158928237499 75VolzA.KupkeA.SongF.JanyS.FuxR.Shams-EldinH.SchmidtJ.BeckerC.EickmannM.BeckerS.Protective efficacy of recombinant modified" exact="vaccinia virus" post="Ankara delivering Middle East respiratory syndrome coronavirus spike glycoproteinJ."/>
   <result pre="against enhancement in Zika virus infectionFront. Immunol.9201859729740424 81GouldE.A.BuckleyA.Antibody-dependent enhancement of" exact="yellow fever" post="and Japanese encephalitis virus neurovirulenceJ. General Virol.70Pt 6198916051608 82Martín-AcebesM.A.SaizJ.-C.Jiménez"/>
   <result pre="virus infectionFront. Immunol.9201859729740424 81GouldE.A.BuckleyA.Antibody-dependent enhancement of yellow fever and Japanese" exact="encephalitis" post="virus neurovirulenceJ. General Virol.70Pt 6198916051608 82Martín-AcebesM.A.SaizJ.-C.Jiménez de OyaN.Antibody-dependent enhancement"/>
   <result pre="Advances in virus researchElsevier2016193218 86VennemaH.De GrootR.HarbourD.DalderupM.Gruffydd-JonesT.HorzinekM.SpaanW.Early death after feline infectious" exact="peritonitis" post="virus challenge due to recombinant vaccinia virus immunizationJ. Virol.6431990140714092154621"/>
   <result pre="death after feline infectious peritonitis virus challenge due to recombinant" exact="vaccinia virus" post="immunizationJ. Virol.6431990140714092154621 87YipM.LeungH.LiP.CheungC.DutryI.LiD.DaeronM.BruzzoneR.PeirisJ.S.JaumeM.Antibody-dependent enhancement of SARS coronavirus infection and"/>
   <result pre="of suboptimal antibody responses in COVID-19Nat. Rev. Immunol.20201331792373 95BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.A double-inactivated" exact="severe acute respiratory syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
   <result pre="response upon challengeJ. Virol.85232011122011221521937658 96YangZ.-Y.WernerH.C.KongW.-P.LeungK.TraggiaiE.LanzavecchiaA.NabelG.J.Evasion of antibody neutralization in emerging" exact="severe acute respiratory syndrome" post="coronavirusesProc. Natl. Acad. Sci.1023200579780115642942 97LuR.ZhaoX.LiJ.NiuP.YangB.WuH.WangW.SongH.HuangB.ZhuN.Genomic characterisation and epidemiology of"/>
   <result pre="Assessment of immunoreactive synthetic peptides from the structural proteins of" exact="severe acute respiratory syndrome" post="coronavirus, Clinical Chemistry 49(12) (2003) 1989-1996. 102TangF.QuanY.XinZ.-T.WrammertJ.MaM.-J.LvH.WangT.-B.YangH.RichardusJ.H.LiuW.Lack of peripheral"/>
   <result pre="105ChannappanavarR.FettC.ZhaoJ.MeyerholzD.K.PerlmanS.Virus-specific memory CD8 T cells provide substantial protection from lethal" exact="severe acute respiratory syndrome" post="coronavirus infectionJ. Virol.88192014110341104425056892 106DuL.HeY.ZhouY.LiuS.ZhengB.-J.JiangS.The spike protein of SARS-CoV–a target"/>
   <result pre="assay of the dynamic changes of serum antibody responses against" exact="severe acute respiratory syndrome" post="coronavirusChin. Med. J.1186200544645015788124 108XuX.GaoX.-M.Immunological responses against SARS-coronavirus infection in"/>
   <result pre="Mol. Immunol.12200411912216212898 109ZhongX.YangH.GuoZ.-F.SinW.-Y.F.ChenW.XuJ.FuL.WuJ.MakC.-K.G.ChengC.-S.S.B-cell responses in patients who have recovered from" exact="severe acute respiratory syndrome" post="target a dominant site in the S2 domain of"/>
   <result pre="Bushmaker, A. Flaxman, M. Ulaszewska, ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaques, bioRxiv (2020). 133ZhuF.-C.LiY.-H.GuanX.-H.HouL.-H.WangW.-J.LiJ.-X.WuS.-P.WangB.-S.WangZ.WangL.Safety, tolerability, and immunogenicity"/>
   <result pre="non-randomised, first-in-human trialThe Lancet2020 134KochT.DahlkeC.FathiA.KupkeA.KrählingV.OkbaN.M.HalweS.RohdeC.EickmannM.VolzA.Safety and immunogenicity of a modified" exact="vaccinia virus" post="Ankara vector vaccine candidate for Middle East respiratory syndrome:"/>
   <result pre="AmerongenG.Geelhoed-MierasM.VerburghR.HeldensJ.BedwellJ.van den BrandJ.KuikenT.van BaalenC.A single immunization with CoVaccine HT-adjuvanted H5N1" exact="influenza" post="virus vaccine induces protective cellular and humoral immune responses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7449865/results/search/disease/results.xml">
   <result pre="vaccines in other historical pandemics such as: smallpox, influenza, malaria," exact="typhoid fever," post="Dengue fever and Zika. Conclusions One possibility to shorten"/>
   <result pre="100% effective, it becomes even more challenging: If we take" exact="influenza" post="as an example, over the last decade, CDC reported"/>
   <result pre="an example, over the last decade, CDC reported efficacy for" exact="influenza" post="vaccine between 19 and 60% [16]. This represents an"/>
   <result pre="to be addressed [18]. Assuming again, the efficacy of the" exact="influenza" post="vaccine would imply a substantial number of volunteers going"/>
   <result pre="that these are experimental vaccines only. Given the case of" exact="influenza" post="vaccination fatality rate of about 0.2% in the age"/>
   <result pre="challenge studies have been used successfully in history for smallpox," exact="yellow fever," post="and malaria. More recent examples of infectious diseases whose"/>
   <result pre="vaccines have been developed more rapidly using this methodology include" exact="typhoid fever," post="cholera, and influenza [23]. Ethical recommendations for planning a"/>
   <result pre="more rapidly using this methodology include typhoid fever, cholera, and" exact="influenza" post="[23]. Ethical recommendations for planning a possible SARS-CoV-2 infection"/>
   <result pre="be ruled out in the case of diseases, such as" exact="anthrax" post="or Ebola, with a high mortality rate [25]. The"/>
   <result pre="income, conceal underlying medical conditions, intake of concomitant medications, or" exact="substance abuse." post="This may expose the volunteers to medical risks, and"/>
   <result pre="reviewed by an independent committee of experts, such as epidemiologists," exact="infectious disease" post="experts, clinical pharmacists, virologists, bioethics experts, etc. (Fig. 1)."/>
   <result pre="to minimize the risks. In the early 1970s, a French" exact="hepatitis" post="B vaccine was first tested on volunteers from the"/>
   <result pre="double antiviral therapy with Peginterferon and ribavirin in patients with" exact="hepatitis" post="C virus infectionFarmacia.202064605611 10.LakdawalaSSMenacheryVDThe search for a COVID-19 animal"/>
   <result pre="healthy volunteers in biomedical researchTheor Med Bioeth201233213714910.1007/s11017-011-9201-122198413 30.GerlichWHMedical virology of" exact="hepatitis" post="B: how it began and where we are nowVirol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7452821/results/search/disease/results.xml">
   <result pre="high-quality T cell response in protective immunity. Yellow Fever and" exact="smallpox" post="vaccines are excellent benchmarks for primary immune response to"/>
   <result pre="[2], [3], [4], [5], [6], [7], [8], [9], [10]. In" exact="severe acute respiratory syndrome" post="(SARS), only 50% of survivors had detectable antibodies at"/>
   <result pre="or absent in mild disease [5]. Experimental infection with a" exact="common cold" post="coronavirus in humans resulted in antibodies that died away"/>
   <result pre="in coronavirus infection in animals and possibly humans. Feline infectious" exact="peritonitis" post="is a coronavirus disease. Severity is worsened by vaccination"/>
   <result pre="antibody titers prior to viral infection [17]. SARS-CoV-1 virus causes" exact="hepatitis" post="in ferrets only in previously vaccinated animals [18]. In"/>
   <result pre="inflammatory cytokines and reduced wound healing [12]. These findings parallel" exact="dengue hemorrhagic fever" post="in humans, where initial infection and antibody response followed"/>
   <result pre="followed by a second infectious episode is required for serious" exact="hemorrhagic disease." post="Subneutralizing antibodies can promote viral entry into cells, including"/>
   <result pre="suboptimal titers of neutralizing antibodies. Vaccine trials for feline infectious" exact="peritonitis" post="and dengue had to be halted because of disease"/>
   <result pre="We are fortunate to have in Yellow Fever (YF) and" exact="smallpox" post="vaccines excellent benchmarks for primary immune response to viral"/>
   <result pre="greater homology to spike proteins in betacoronviruses that cause the" exact="common cold." post="Prevalence of T-cells that are reactive to SARS-CoV-2 proteins"/>
   <result pre="of highly effective viral vaccines - in particular, YF and" exact="smallpox" post="vaccinations [1], [36]. To understand the basis of long-lived,"/>
   <result pre="very different for COVID-19 [42]. There was extensive experience with" exact="influenza" post="vaccine technology and vaccines made using well established platforms"/>
   <result pre="References References 1AhmedR.AkondyR.S.Insights into human CD8(+) T-cell memory using the" exact="yellow fever" post="and smallpox vaccinesImmunol Cell Biol893201134034521301482 2TangF.QuanY.XinZ.T.Lack of peripheral memory"/>
   <result pre="into human CD8(+) T-cell memory using the yellow fever and" exact="smallpox" post="vaccinesImmunol Cell Biol893201134034521301482 2TangF.QuanY.XinZ.T.Lack of peripheral memory B cell"/>
   <result pre="hospitalized patients with COVID-2019Nature5817809202046546932235945 17VennemaH.de GrootR.J.HarbourD.A.Early death after feline infectious" exact="peritonitis" post="virus challenge due to recombinant vaccinia virus immunizationJ Virol641990140714092154621"/>
   <result pre="death after feline infectious peritonitis virus challenge due to recombinant" exact="vaccinia virus" post="immunizationJ Virol641990140714092154621 18WeingartlH.CzubM.CzubS.Immunization with modified vaccinia virus Ankara-based recombinant"/>
   <result pre="due to recombinant vaccinia virus immunizationJ Virol641990140714092154621 18WeingartlH.CzubM.CzubS.Immunization with modified" exact="vaccinia virus" post="Ankara-based recombinant vaccine against severe acute respiratory syndrome is"/>
   <result pre="Virol641990140714092154621 18WeingartlH.CzubM.CzubS.Immunization with modified vaccinia virus Ankara-based recombinant vaccine against" exact="severe acute respiratory syndrome" post="is associated with enhanced hepatitis in ferretsJ Virol78222004126721267615507655 19CaoX.COVID-19:"/>
   <result pre="vaccine against severe acute respiratory syndrome is associated with enhanced" exact="hepatitis" post="in ferretsJ Virol78222004126721267615507655 19CaoX.COVID-19: immunopathology and its implications for"/>
   <result pre="infected with 2019 novel coronavirus in WuhanChina Lancet39510223202049750631986264 22BollesM.DemingD.LongK.A double-inactivated" exact="severe acute respiratory syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
   <result pre="25ChannappanavarR.FettC.ZhaoJ.MeyerholzD.K.PerlmanS.Virus-specific memory CD8 T cells provide substantial protection from lethal" exact="severe acute respiratory syndrome" post="coronavirus infectionJ Virol882014110341104425056892 26ZhaoJ.ZhaoJ.PerlmanS.T cell responses are required for"/>
   <result pre="for protection from clinical disease and for virus clearance in" exact="severe acute respiratory syndrome" post="coronavirus-infected miceJ Virol841820109318932520610717 27Janice OhH.L.Ken-En GanS.BertolettiA.TanY.J.Understanding the T cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7455144/results/search/disease/results.xml">
   <result pre="the experience of Samoa, which was recently impacted by a" exact="measles" post="epidemic, the authors discuss the importance of vaccination to"/>
   <result pre="81 reported deaths and 5,675 reported cases (Outbreak, 2019) of" exact="measles" post="from an epidemic in 2019. Although no inquiry into"/>
   <result pre="in declaring the outbreak and state of emergency, unavailability of" exact="measles" post="diagnostic tests locally, poor communication and leadership, lack of"/>
   <result pre="the misinformation about side effects about vaccinations being linked to" exact="autism" post="and toxins in the vaccines themselves (Hoffman et al.,"/>
   <result pre="the documented reports of side effects such as cases of" exact="narcolepsy" post="after receiving the H1N1 vaccine (Lundgren, 2015), minimizing the"/>
   <result pre="[cited 2020 May 4]. Available from: https://www.immune.org.nz/hot-topic/infant-deaths-samoa-tragic-outcome-error-preparing-mmr-vaccine. Kerr F. Samoa" exact="measles" post="outbreak: Edwin Tamasese first anti-vaxxer [Internet]. Stuff.co.NZ; 2019 Dec"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7461084/results/search/disease/results.xml">
   <result pre="the whole world in tenterhooks due to its severe life‐threatening" exact="infectious disease," post="COVID‐19. The virus is distinct its cousins, SARS‐CoV and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7461519/results/search/disease/results.xml">
   <result pre="guiding stakeholder engagement in planning a pragmatic study on changing" exact="stroke" post="systems of care. J Clin Transl Sci. 1(2), 121‐128."/>
   <result pre="(2018). Considerations for community engagement when conducting clinical trials during" exact="infectious disease" post="emergencies in West Africa. Dev World Bioeth. 1–10. stakeholder"/>
   <result pre="Haire, B., Allman, D., et al. (2018). Research priorities during" exact="infectious disease" post="emergencies in West Africa. BMC Research Notes. 11(1), 159."/>
   <result pre="competencies to conduct community‐led monitoring programs for HIV, tuberculosis, and" exact="malaria" post="programs in the region. 45Healthgaps. (2019). Community led monitoring"/>
   <result pre="Pathogens Treatment Consortium. Her research interests are ethical issues in" exact="infectious disease" post="control with an emphasis on underserved or marginalised populations,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7462473/results/search/disease/results.xml">
   <result pre=": Article Is it time to reconsider measles, mumps, and" exact="rubella" post="immunisation strategies? BoccaliniSaraaBechiniAngelaa[a], pmc-release: 2020-9-9epub: 2020-9-9(C) Elsevier Ltd, 2020Since"/>
   <result pre="the COVID-19 resource centre remains active. Since the late 1990s," exact="measles" post="has continued to be a public health problem, and"/>
   <result pre="health problem, and so WHO launched a global plan for" exact="measles" post="and congenital rubella elimination in 1997. Despite the relevant"/>
   <result pre="so WHO launched a global plan for measles and congenital" exact="rubella" post="elimination in 1997. Despite the relevant efforts, the goals"/>
   <result pre="areas where high immunisation coverage has been registered, epidemics of" exact="measles" post="have occurred in the past 10 years worldwide.1, 2,"/>
   <result pre="cutoff level of seropositivity for protection against measles, mumps, and" exact="rubella" post="will allow results that are comparable between laboratories and"/>
   <result pre="failure, as reported by Schenk and colleagues. References References 1BernardHFischerRWildFOngoing" exact="measles" post="outbreak in southern Bavaria, GermanyEuro Surveill1320088002 2SianiAMeasles outbreaks in"/>
   <result pre="re-emergence of vaccine-preventable diseases in developed countriesPrev Med12120199910430763627 3SmithsonRIrvineNHuttonCDohertyLWattASpotlight on" exact="measles" post="2010: ongoing measles outbreak in Northern Ireland following an"/>
   <result pre="diseases in developed countriesPrev Med12120199910430763627 3SmithsonRIrvineNHuttonCDohertyLWattASpotlight on measles 2010: ongoing" exact="measles" post="outbreak in Northern Ireland following an imported case, September-October"/>
   <result pre="Vaccines18201969370131268739 6SchenkJAbramsSTheetenHVan DammePBeutelsPHensNImmunogenicity and persistence of trivalent measles, mumps, and" exact="rubella" post="vaccines: a systematic review and meta-analysisLancet Infect Dis2020published online"/>
   <result pre="Infect Dis2020published online Sept 1.10.1016/S1473-3099(20)30442-4 7BechiniALeviMBoccaliniSProgress in the elimination of" exact="measles" post="and congenital rubella in central ItalyHum Vaccin Immunother9201364965623292174 8BramerCAKimminsLMSwansonRDecline"/>
   <result pre="Sept 1.10.1016/S1473-3099(20)30442-4 7BechiniALeviMBoccaliniSProgress in the elimination of measles and congenital" exact="rubella" post="in central ItalyHum Vaccin Immunother9201364965623292174 8BramerCAKimminsLMSwansonRDecline in child vaccination"/>
   <result pre="immunization and risk perception of measles, rubella, mumps, varicella, and" exact="pertussis" post="in health care workers working in 6 hospitals of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7462568/results/search/disease/results.xml">
   <result pre="a city in the Hubei province of China, causing severe" exact="pneumonia" post="that leads to huge death cases (Wang et al.,"/>
   <result pre="common clinical manifestations of COVID-19 are fever, sputum production and" exact="shortness" post="in breath, cough, fatigue, sore throat and headache which"/>
   <result pre="of pneumonia. A few patients also have gastrointestinal symptoms with" exact="diarrhea" post="and vomiting (Guan et al., 2020). Though several early"/>
   <result pre="is well conserved in coronavirus and also found in murine" exact="hepatitis" post="virus. On the other hands, the gamma coronavirus shows"/>
   <result pre="of deleterious missense mutations in 894 autophagy related proteins on" exact="hepatocellular carcinoma" post="(HCC): a comprehensive 895 informatics approachInt. J. Mol. Sci.181201713910.3390/ijms18010139"/>
   <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751310.1016/S0140-6736(20)30211-732007143 CooperN.R.NemerowG.R.The role of"/>
   <result pre="target for vaccine and therapeutic developmentNat. Rev. Microbiol.732009226236(Mar)19198616 EminiE.A.HughesJ.V.PerlowD.BogerJ.Induction of" exact="hepatitis" post="a virus-neutralizing antibody by a virus-specific synthetic peptideJ. Virol.5531985836839(Sep"/>
   <result pre="effects of feline IL-12 during DNA vaccination against feline infectious" exact="peritonitis" post="virusJ. Gen. Virol.8312002110(Jan 1)11752695 GorbalenyaA.E.LauberC.Phylogeny of virusesReference Module in"/>
   <result pre="vaccinology approach to design a novel multi-epitope subunit vaccine against" exact="avian influenza" post="A (H7N9) virusMicrob. Pathog.1302019193710.1016/j.micpath.2019.02.02330822457 HasanM.IslamS.ChakrabortyS.MustafaA.H.AzimK.F.JoyZ.F.Contriving a chimeric polyvalent vaccine"/>
   <result pre="approach to design a novel multi-epitope subunit vaccine against avian" exact="influenza" post="A (H7N9) virusMicrob. Pathog.1302019193710.1016/j.micpath.2019.02.02330822457 HasanM.IslamS.ChakrabortyS.MustafaA.H.AzimK.F.JoyZ.F.Contriving a chimeric polyvalent vaccine"/>
   <result pre="HasanM.IslamS.ChakrabortyS.MustafaA.H.AzimK.F.JoyZ.F.Contriving a chimeric polyvalent vaccine to prevent infections caused by" exact="herpes simplex" post="virus (Type-1 and Type-2): an exploratory immunoinformatic approachJ. Biomol."/>
   <result pre="coronavirusNature.4266965200345045410.1038/nature0214514647384 LiW.JoshiM.SinghaniaS.RamseyK.MurthyA.Peptide vaccine: progress and challengesVaccines.23201451553610.3390/vaccines203051526344743 LiuJ.SunY.QiJ.ChuF.WuH.GaoF.LiT.YanJ.GaoG.F.The membrane protein of" exact="severe acute respiratory syndrome" post="coronavirus acts as a dominant immunogen revealed by a"/>
   <result pre="internal coordinates normal mode analysis serverNucleic Acids Res.42W12014W271W27610.1093/nar/gku33924771341 LuH.StrattonC.W.TangY.Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan China: the mystery and"/>
   <result pre="and morphologyJ. Struct. Biol.174120111122(Apr 1)21130884 Nieto-TorresJ.L.DeDiegoM.L.ÁlvarezE.Jiménez-GuardeñoJ.M.Regla-NavaJ.A.LlorenteM.Subcellular location and topology of" exact="severe acute respiratory syndrome" post="coronavirus envelope proteinVirology.41522011698210.1016/j.virol.2011.03.02921524776 OanyA.R.EmranA.A.JyotiT.P.Design of an epitope-based peptide vaccine"/>
   <result pre="vaccine, and passive immunization for prevention of West Nile virus" exact="encephalitis" post="in hamster modelEmerg. Infect. Dis.812200213921397(Dec)10.3201/eid0812.02022912498653 ThompsonA.L.StaatsH.F.Cytokines: the future of"/>
   <result pre="health concernLancet395102232020470473(Internet] Elsevier BV. (Feb)10.1016/s0140-6736(20)30185-931986257 WasmoenT.L.KadakiaN.P.UnferR.C.FickbohmB.L.CookC.P.ChuH.J.AcreeW.M.Protection of cats from infectious" exact="peritonitis" post="by vaccination with a recombinant raccoon poxvirus expressing the"/>
   <result pre="recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious" exact="peritonitis" post="virusCorona And Related Viruses1995SpringerBoston, MA221228 WaterhouseA.M.ProcterJ.B.MartinD.M.A.ClampM.BartonG.J.Jalview version 2-a multiple"/>
   <result pre="version 2-a multiple sequence alignment editor and analysis workbenchBioinformatics.25920091189119110.1093/bioinformatics/btp03319151095 WesselingJ.G.GodekeG.J.SchijnsV.E.PrevecL.GrahamF.L.HorzinekM.C.RottierP.J.Mouse" exact="hepatitis" post="virus spike and nucleocapsid proteins expressed by adenovirus vectors"/>
   <result pre="COVID-19 and SARS-related coronavirusesbioRxiv.202010.1101/2020.03.04.975995 WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature.5797798202026526910.1038/s41586-020-2008-332015508 WüthrichK.WagnerG.RicharzR.BraunW.Correlations between internal mobility and stability of"/>
   <result pre="3)30058403 ZhouY.HouY.ShenJ.HuangY.MartinW.ChengF.Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2Cell Discov.61202011810.1038/s41421-020-0153-331934347 ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="of probable bat originNature.5797798202027027310.1038/s41586-020-2012-732015507 ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.3828202072773310.1056/nejmoa200101731978945 ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.-Y.Coronaviruses-drug discovery and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7462898/results/search/disease/results.xml">
   <result pre="prevention of COVID-19. Abstract Coronavirus disease-19 (COVID-19) is caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related to two"/>
   <result pre="breakouts in humans in the last 2 decades, namely, severe" exact="acute respiratory distress syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)."/>
   <result pre="global impact. The disease is caused by a coronavirus called" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe acute"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 along with severe" exact="acute respiratory distress syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) are the"/>
   <result pre="are involved not only in viral replication but also in" exact="suppression" post="of the host defenses by various mechanisms, including degradation"/>
   <result pre="of mechanisms to evade detection by the host-immune response, including" exact="suppression" post="of host interferon response, mimicking host 5’ cap on"/>
   <result pre="COVID-19, including age, biological sex, pre-existing medical conditions, such as" exact="cardiovascular disease," post="diabetes, and obesity. Otherwise, the reasons for: inter-individual variability"/>
   <result pre="comorbid conditions. About 5% of the infected symptomatic patients develop" exact="acute respiratory distress syndrome" post="and require oxygen supplementation through intubation and other invasive"/>
   <result pre="and partly because of the presence of concomitant cardiovascular diseases," exact="diabetes mellitus" post="and others. Although males and females are equally susceptible"/>
   <result pre="SARS-CoV-2 depends on coexpression of ACE2 and host proteases, viral" exact="myocarditis" post="is not a common feature of COVID-19. However, histological"/>
   <result pre="thrombosis, and heart failure (reviewed in [33,34,35]). More importantly, concomitant" exact="cardiovascular disease" post="and secondary cardiac involvement are major determinants of clinical"/>
   <result pre="patients with COVID-19 [36,37]. Coagulopathy, represented by increased D-Dimer levels," exact="disseminated intravascular coagulation" post="(DIC), and thrombocytopenia, and thrombotic events, is a common"/>
   <result pre="available and are currently being used for treatment of chronic" exact="pancreatitis" post="and cystic fibrosis, respectively. Preclinical studies show treatment with"/>
   <result pre="are currently being used for treatment of chronic pancreatitis and" exact="cystic fibrosis," post="respectively. Preclinical studies show treatment with camostat mesylate blocks"/>
   <result pre="vector, such as plasmids, replication-deficient adenoviruses, lentiviruses, or replication-competent vesicular" exact="stomatitis" post="virus, to transfer a SARS-CoV-2 gene and express a"/>
   <result pre="classic antigens for vaccine generation, dating back to vaccination against" exact="smallpox" post="by Edward Jenner who coined the term vaccination. The"/>
   <result pre="of diseases. Declaration of competing interest None. References References 1ZhouPYangXLWangXGHuBZhangLZhangWA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="of probable bat originNature579202027027332015507 2WuFZhaoSYuBChenYMWangWSongZGA new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature579202026526932015508 3BartlamMYangHRaoZStructural insights into SARS coronavirus proteinsCurr Opin"/>
   <result pre="spike glycoproteinCell1812020281292e632155444 5ShangJYeGShiKWanYLuoCAiharaHStructural basis of receptor recognition by SARS-CoV-2Nature581202022122432225175 6DeDiegoMLAlvarezEAlmazanFRejasMTLamirandeERobertsAA" exact="severe acute respiratory syndrome" post="coronavirus that lacks the E gene is attenuated in"/>
   <result pre="and only proteolysis by TMPRSS2 augments entry driven by the" exact="severe acute respiratory syndrome" post="coronavirus spike proteinJ Virol8820141293130724227843 14ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNSARS-CoV-2 receptor ACE2 is an"/>
   <result pre="and population levelsmedRxiv.2020, 2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte antigen susceptibility map for" exact="severe acute respiratory syndrome" post="coronavirus 2J Virol94132020e00510e0052032303592 24RichardsonSHirschJSNarasimhanMCrawfordJMMcGinnTDavidsonKWPresenting characteristics, comorbidities, and outcomes among"/>
   <result pre="for COVID-19. A randomized clinical trialmedRxiv.2020202007.01.20139857 48HatesuerBBertramSMehnertNBahgatMMNelsonPSPohlmannSTmprss2 is essential for" exact="influenza" post="H1N1 virus pathogenesis in micePLoS Pathog92013e1003774 49YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIIdentification of nafamostat"/>
   <result pre="cases of treatment with nafamostat in elderly patients with COVID-19" exact="pneumonia" post="who need oxygen therapyInt J Infect Dis96202050050232470602 51CortegianiAIppolitoMIngogliaGIozzoPGiarratanoAEinavSUpdate I."/>
   <result pre="double-blind, placebo-controlled, multicentre trialLancet39520201569157832423584 58AntinoriSCossuMVRidolfoALRechRBonazzettiCPaganiGCompassionate remdesivir treatment of severe Covid-19" exact="pneumonia" post="in intensive care unit (ICU) and Non-ICU patients: clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7464065/results/search/disease/results.xml">
   <result pre="novel coronavirus (2019-nCoV) by the World Health Organization (WHO) and" exact="severe acute respiratory syndrome" post="coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of"/>
   <result pre="for emerging infectious diseases. The news of numerous cases of" exact="pneumonia" post="was reported from December 31, 2019, with unknown aetiology"/>
   <result pre="too, belongs to the family of viruses that include the" exact="common cold," post="and viruses of SARS and MERS [19–21]. The available"/>
   <result pre="(Table 2). Samples from seven patients initially complaining of severe" exact="pneumonia" post="were used in the report. It was found that"/>
   <result pre="and SARS-CoV-2) The Coronaviruses were known to cause only mild" exact="respiratory disease" post="in humans, with severe infections in the immunocompromised cases"/>
   <result pre="and now SARS-CoV-2. Seldom coronaviruses cause lower respiratory infection or" exact="pneumonia" post="but SARS-CoV-2 causes. Coronaviruses have seasonal pattern usually affecting"/>
   <result pre="syndrome followed by severe pulmonary damage and death due to" exact="respiratory failure." post="Additionally, all the blood cells except neutrophils were reported"/>
   <result pre="with heavy involvement of the brainstem. In this context, acute" exact="respiratory failure" post="among COVID-19 patients suggests the probable invasion of the"/>
   <result pre="signs [80]. Those who developed severe pneumonia, pulmonary oedema, hypoxemic" exact="respiratory failure," post="gastrointestinal infection, multiple system failure, or Acute Respiratory Distress"/>
   <result pre="of clinical symptoms like fever, cough, myalgia, and fatigue with" exact="pneumonia" post="[25, 40, 87]. To overcome the symptoms of novel"/>
   <result pre="assessed [159]. LAM-002A 9 (apilimod), a drug used to treat" exact="follicular lymphoma" post="and autoimmune diseases have proven effective against SAR-CoV-2. Yale"/>
   <result pre="[159]. LAM-002A 9 (apilimod), a drug used to treat follicular" exact="lymphoma" post="and autoimmune diseases have proven effective against SAR-CoV-2. Yale"/>
   <result pre="among others. Viral polymerase and protease inhibitors of HIV and" exact="hepatitis" post="C virus are two potential antiviral regimens that can"/>
   <result pre="its revised guidelines for the prevention, diagnosis, and treatment of" exact="pneumonia" post="developed due to COVID-19 infection in the vast populous"/>
   <result pre="as treatment options [18]. EIDD-2801 compound has proven effective against" exact="influenza" post="viruses and can be evaluated against SARS-CoV-2 as well"/>
   <result pre="useful therapeutic option in reducing the lung inflammation and treating" exact="pneumonia" post="in COVID-19 patients [186, 187]. The virus attachment through"/>
   <result pre="for animals and humans affected by viral infections like the" exact="influenza" post="virus, West Nile virus, hepatitis virus, herpes virus, papillomavirus,"/>
   <result pre="by viral infections like the influenza virus, West Nile virus," exact="hepatitis" post="virus, herpes virus, papillomavirus, and HIV. In this context,"/>
   <result pre="macaques challenged with SARS-CoV-2 compared with control animals, and no" exact="pneumonia" post="was observed in vaccinated animals. However, there was no"/>
   <result pre="Brownlie et al. [239] 2017-10-12 WO2017176596A1 Vaccine Multivalent vaccines for" exact="rabies" post="virus and coronaviruses The present disclosure provides methods and"/>
   <result pre="dual protection against infections by either or both of a" exact="rabies" post="virus and a coronavirus, and which can be used"/>
   <result pre="can be used therapeutically for an existing infection with the" exact="rabies" post="virus and a coronavirus to treat at least one"/>
   <result pre="infecting agents. In particular, the present disclosure provides a recombinant" exact="rabies" post="virus vector comprising a nucleotide sequence encoding at least"/>
   <result pre="human subject suffering from or at risk of developing an" exact="autoimmune disease," post="disorder or condition Administering a pharmaceutical composition, wherein the"/>
   <result pre="tolerance in the subject against the antigen that mediates the" exact="autoimmune disease," post="disorder or condition Jordi et al. [234] 2020-01-02 US20200002370A1"/>
   <result pre="Drug/treatment Use of radotinib for prevention or treatment of viral" exact="respiratory disease" post="The present invention relates to a new use of"/>
   <result pre="Formula 1 (radotinib) in the prevention or treatment of viral" exact="respiratory disease." post="According to the present invention, a compound of Chemical"/>
   <result pre="the speed of response against a pathogenic antigen or a" exact="cancer" post="antigen. A two-step prime-boost method whereby the immune system"/>
   <result pre="of Abbvie®. They are patented for use against viruses (Ebola)," exact="malaria" post="and HIV/AIDS, respectively, however, have shown potential for application"/>
   <result pre="with the SARS-CoV-2 divergenceCurr Trop Med Rep.2020737578 30.Villamizar-PenaRGutierrez-OcampoERodriguez-MoralesAJPooled prevalence of" exact="diarrhea" post="among COVID-19 PatientsClin Gastroenterol Hepatol.202018102385238732425705 31.GuiMSongWZhouHXuJChenSXiangYWangXCryo-electron microscopy structures of"/>
   <result pre="recent developmentsVet Q2020401687632036774 40.ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRet al.A Novel Coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773331978945 41.Wang M, Wu"/>
   <result pre="al. Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. bioRxiv."/>
   <result pre="Yip CC-Y, Poon RW-S et al: A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
   <result pre="Biol20203071346135132197085 74.Features, Evaluation and Treatment Coronavirus (COVID-19). https://www.ncbi.nlm.nih.gov/books/NBK554776/. 75.LuHStrattonCWTangY-WOutbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: The mystery and"/>
   <result pre="the2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 88.Yu L, Wu S,"/>
   <result pre="B-L. Clinical and computed tomographic imaging features of novel coronavirus" exact="pneumonia" post="caused by SARS-CoV-2. J Infect. 2020. 93.WangWXuYGaoRLuRHanKWuGTanWDetection of SARS-CoV-2"/>
   <result pre="infection during Colombia epidemic, 2015-2016Travel Med Infect Dis201614327427627060613 105.Rodriguez-MoralesAJZika and" exact="microcephaly" post="in Latin America: An emerging threat for pregnant travelers?Travel"/>
   <result pre="(CTAP). https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap. Accessed 13 Aug 2020. 114.Millan-OnateJMillanWMendozaLASanchezCGFernandez-SuarezHBonilla-AldanaDKRodriguez-MoralesAJSuccessful recovery of COVID-19" exact="pneumonia" post="in a patient from Colombia after receiving chloroquine and"/>
   <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, ChinaMicrobes Infect2020222747932017984 121.LiuCZhouQLiYGarnerLVWatkinsSPCarterLJSmootJGreggACDanielsADJerveySet al.Research and"/>
   <result pre="2020. 156.PanXDongLYangLChenDPengCPotential drugs for the treatment of the novel coronavirus" exact="pneumonia" post="(COVID-19) in ChinaVirus Res202028619805732531236 157.SharunKDhamaKPatelSKPathakMTiwariRSinghBRSahRBonilla-AldanaDKRodriguez-MoralesAJLeblebiciogluHIvermectin, a new candidate therapeutic"/>
   <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil Med Res2020714432029004 166.RobackJDGuarnerJConvalescent plasma to treat COVID-19:"/>
   <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBioScience Trends2020141646832037389 173.SheahanTPSimsACLeistSRSchäferAWonJBrownAJMontgomerySAHoggABabusisDClarkeMOet"/>
   <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBioScience Trends2020141727332074550 176.LinLLiTSInterpretation of &quot;Guidelines for the"/>
   <result pre="coronavirus modelChin Med J (Engl)202013391051105632149769 178.TootsMYoonJ-JCoxRMHartMSticherZMMakhsousNPleskerRBarrenaAHReddyPGMitchellDGet al.Characterization of orally efficacious" exact="influenza" post="drug with high resistance barrier in ferrets and human"/>
   <result pre="Dis202020552352432145766 195.MarraroGASpadaCConsideration of the respiratory support strategy of severe acute" exact="respiratory failure" post="caused by SARS-CoV-2 infection in childrenZhongguo Dang Dai Er"/>
   <result pre="on SARS-CoV immunological studies. bioRxiv 2020:2020.2002.2003.933226. 201.ShangWYangYRaoYRaoXThe outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesVaccines2020511832194995 202.PatelSKPathakMTiwariRYatooMIMalikYSSahRRabaanAASharunKDhamaKBonilla-AldanaDKet al.A vaccine is not"/>
   <result pre="A, Ulaszewska M et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaques. Nature. 2020. 211.Folegatti PM, Ewer KJ,"/>
   <result pre="we?Expert Rev Vaccines20098788789819538115 219.WuFZhaoSYuBChenY-MWangWSongZ-GHuYTaoZ-WTianJ-HPeiY-Yet al.A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature2020579779826526932015508 220.BukreyevALamirandeEWBuchholzUJVogelLNElkinsWRClaireMSMurphyBRSubbaraoKCollinsPLMucosal immunisation of African green monkeys (Cercopithecus"/>
   <result pre="JS. Use of radotinib for prevention or treatment of viral" exact="respiratory disease." post="2017. 233.Radtke KL PH, Neyts J, Jochmans D, Snijder"/>
   <result pre="LE, Wirblich C, Coleman CM, Frieman MB. Multivalent vaccines for" exact="rabies" post="virus and coronaviruses. 2017 238.Sutter G FR, Volz A,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7466941/results/search/disease/results.xml">
   <result pre="virus—SARS-CoV-2—is the seventh coronavirus known to infect humans and cause" exact="severe acute respiratory syndrome." post="When this coronavirus pandemic broke out it transformed the"/>
   <result pre="series of different drug candidates have already been patented for" exact="severe acute respiratory syndrome" post="(SARS) virus (SARS-CoV), including Middle East respiratory syndrome (MERS)"/>
   <result pre="era in vaccinologyNat. Rev. Drug Discov.17201826127929326426 6JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and" exact="severe acute respiratory syndrome" post="coronavirus infection depend on differentiation of human airway epitheliaJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7467145/results/search/disease/results.xml">
   <result pre="(antiviral: guanine derivative) RdRp Inhibit RNA polymerization (1) RSV infection," exact="hepatitis" post="C, some viral hemorrhagic fevers (2) In case of"/>
   <result pre="underway Oseltamivir [66] (antiviral) Neuraminidase enzyme Inhibits neuraminidase enzyme in" exact="influenza" post="Used in influenza patient. This drug is used for"/>
   <result pre="(antiviral) Neuraminidase enzyme Inhibits neuraminidase enzyme in influenza Used in" exact="influenza" post="patient. This drug is used for repurposing only in"/>
   <result pre="(2) Inhibits viral-host cell fusion (1) An antiviral treatment for" exact="influenza" post="infection used in Russia and China (2) Proposed reduction"/>
   <result pre="been proven effective in treating coronavirus in China (2) Treating" exact="pneumonia" post="patients with SARS-CoV-2 infection Approved for clinical trial against"/>
   <result pre="inhibitor (JAK) Affects the inflammatory processes (1) Approved drug for" exact="rheumatoid arthritis" post="(2) Used to treat acute respiratory disease in COVID-19"/>
   <result pre="(JAK) Affects the inflammatory processes (1) Approved drug for rheumatoid" exact="arthritis" post="(2) Used to treat acute respiratory disease in COVID-19"/>
   <result pre="Approved drug for rheumatoid arthritis (2) Used to treat acute" exact="respiratory disease" post="in COVID-19 patients Eli Lilly has announced plans to"/>
   <result pre="initiate parallel prospective, interventional studies with mavrilimumab in patients with" exact="pneumonia" post="and hyper-inflammation caused by SARS-Cov-2. Kiniksa also reported that"/>
   <result pre="therapy. It can aid cytokine-mediated immunopathology of lung injury and" exact="acute respiratory distress syndrome" post="(ARDS) On 2 April 2020, FDA authorized the use"/>
   <result pre="with lenzilumab for the prevention of ARDS in patients with" exact="pneumonia" post="caused by SARS-CoV-2 Leronlimab [75] (monoclonal antibody) CytoDyn (as"/>
   <result pre="can be used for the treatment of CCR5-positive metastatic triple-negative" exact="breast cancer." post="It is also used in antiretroviral therapy (HAART) in"/>
   <result pre="(PD-1) Programmed cell death 1 (PD-1) inhibitor (1) Classical Hodgkin" exact="lymphoma" post="(2) Treat pneumonia (3) Sepsis Phase-II clinical trials (NCT04268537)"/>
   <result pre="death 1 (PD-1) inhibitor (1) Classical Hodgkin lymphoma (2) Treat" exact="pneumonia" post="(3) Sepsis Phase-II clinical trials (NCT04268537) Eculizumab [Soliris] [81]"/>
   <result pre="for acute lung injury (ALI) and/or ARDS in COVID-19 through" exact="suppression" post="of pulmonary edema Under clinical trial (NCT04275414) Bevacizumab, an"/>
   <result pre="lung injury (ALI) and/or ARDS in COVID-19 through suppression of" exact="pulmonary edema" post="Under clinical trial (NCT04275414) Bevacizumab, an anti-VEGF drug, approved"/>
   <result pre="cytokines Used for the treatment of graft-versus-host disease (GVHD) in" exact="leukemia" post="patients receiving hematopoietic stem cell transplantation OncoImmune is planning"/>
   <result pre="to treat COVID-19 induced ARDS. Used for heart attacks or" exact="stroke" post="Under clinical trial. A recent report suggested that the"/>
   <result pre="processes by the inhibition of TNF alpha Effective against COVID-19" exact="pneumonia" post="Under clinical trials (NCT04323514) Box 1 Miscellaneous therapeutics under"/>
   <result pre="protease inhibitor), Ritonavir and interferon (approved in China to treat" exact="hepatitis" post="C, developed by Ascletis; clinical stage), ASC09 (HIV protease"/>
   <result pre="fusion, thus preventing the viral entry into host cells against" exact="influenza" post="virus [37–39]. Camostat mesylate The serine protease TMPRSS2 produced"/>
   <result pre="is also able to inhibit virus infection proficiently in human" exact="liver cancer" post="Huh-7 cells sensitive to COVID-19. A recent case study"/>
   <result pre="also able to inhibit virus infection proficiently in human liver" exact="cancer" post="Huh-7 cells sensitive to COVID-19. A recent case study"/>
   <result pre="available, this drug is able to inhibit the exacerbation of" exact="pneumonia" post="patients with SARS-CoV-2 infection. Fig. 8 Schematic representation of"/>
   <result pre="for manufacturing and sale in Japan for the treatment of" exact="influenza" post="as an antiviral. In case of Influenza virus, it"/>
   <result pre="treatment benefit.&quot; Among those trials, two trials are investigating against" exact="pneumonia" post="caused by COVID-19. One trial is conducted in the"/>
   <result pre="and ventricular arrhythmias), Ear and labyrinth disorders, Eye disorders (Irreversible" exact="retinopathy" post="with retinal pigmentation changes), maculopathies (macular degeneration), decreased dark"/>
   <result pre="inducer Mild: Gastrointestinal disorders Serious: Hyperlipidemia, cardiac conduction disorders, hepatotoxicity," exact="pancreatitis" post="Losartan [34] Initial dose: 50 mg orally once a"/>
   <result pre="benazepril/lisinopril, birth control pills containing drospirenone Mild: Dizziness, chest pain," exact="hypoglycemia" post="Serious: Hyperkalemia, hypotension, and orthostatic hypotension Remdesivir [14, 57–59,"/>
   <result pre="tuberculosis), headache, nasopharyngitis, hypertension Serious: Gastrointestinal perforations, hematologic effects, hepatotoxicity," exact="hypersensitivity" post="reactions Umifenovir (Arbidol) [38, 39, 89] 200 mg every"/>
   <result pre="in the market. It is made from live, attenuated bovine" exact="tuberculosis" post="bacillus, Mycobacterium bovis which induces an adaptive immune response"/>
   <result pre="bacillus, Mycobacterium bovis which induces an adaptive immune response against" exact="tuberculosis" post="bacterium. Due to availability in the market, they utilize"/>
   <result pre="declare. References References 1.WuFZhaoSYuBet al.A new coronavirus associated with human" exact="respiratory disease" post="in ChinaNature202057926526932015508 2.ZhouPYangX-LWangX-Get al.A pneumonia outbreak associated with a"/>
   <result pre="coronavirus associated with human respiratory disease in ChinaNature202057926526932015508 2.ZhouPYangX-LWangX-Get al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="Microbiol Infect Dis20183736336929214503 5.ZhuNZhangDWangWet al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202038272773331978945 6.LiXZaiJWangXLiYPotential of large"/>
   <result pre="of optimized dosing design of hydroxychloroquine for the treatment of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732857833 12.FantiniJDi ScalaCChahinianHYahiNStructural and molecular"/>
   <result pre="35.GlowackaIBertramSHerzogPet al.Differential downregulation of ACE2 by the spike proteins of" exact="severe acute respiratory syndrome" post="coronavirus and human coronavirus NL63J Virol2010841198120519864379 36.WuYCompensation of ACE2"/>
   <result pre="ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04252885. Accessed 11 May 2020 39.KadamRUWilsonIAStructural basis of" exact="influenza" post="virus fusion inhibition by the antiviral drug ArbidolProc Natl"/>
   <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends202014727332074550 44.Al-BariMAATargeting endosomal acidification by chloroquine"/>
   <result pre="to test coronavirus treatmentsNature202057834734832071447 46.MifsudEJHaydenFGHurtACAntivirals targeting the polymerase complex of" exact="influenza" post="virusesAntivir Res201916910454531247246 47.LiuXWangXJPotential inhibitors against 2019-nCoV coronavirus M protease"/>
   <result pre="trial to assess common anti-clotting medication for treatment of COVID-19-related" exact="respiratory failure." post="BIDMC. https://www.bidmc.org/about-bidmc/news/2020/04/covid-19-anti-clotting-medication. Accessed 11 May 2020 87.Clinical management of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7468088/results/search/disease/results.xml">
   <result pre="Phase 1/2 PACTR202006922165132 2020-001072-15 MERS, influenza, TB, Chikungunya, Zika, MenB," exact="plague" post="Non-Replicating Viral Vector Adenovirus type 5 vector CanSino Biological"/>
   <result pre="Thomas Jefferson University where the platform would be vero cell" exact="rabies" post="vaccine in which spike protein RNA shall be introduced."/>
   <result pre="are at high risk including children, immunocompromised, senior citizens, diabetes," exact="heart disease" post="etc. The safety of the vaccine can only be"/>
   <result pre="Spencer A, et al. CHAdOX1 nCov-19 vaccination prevents SARS Cov2" exact="pneumonia" post="in Rhesus Macques. Available at: Pre print 10.1101/2020.05.13.09315 dated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7470735/results/search/disease/results.xml">
   <result pre="the era of COVID-19 and the worldwide anticipation of a" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) vaccine, it might appear as if"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7472682/results/search/disease/results.xml">
   <result pre="pandemic. Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) is the most formidable challenge to"/>
   <result pre="brought the world to a standstill. The respiratory viral pathogen" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) has infected at least 20.1 million"/>
   <result pre="in the early phase of infection resulting from innate immune" exact="suppression" post="probably underpins the ensuing dysregulated inflammatory responses16,21, particularly in"/>
   <result pre="burden and dysregulated, potentially lethal, inflammatory responses and immunopathology, including" exact="acute respiratory distress syndrome." post="For this reason, seniors and those with co-morbidities may"/>
   <result pre="are under way to assess the effects of BCG or" exact="measles" post="vaccination on COVID-19 (ref.178). A COVID-19 vaccine that can"/>
   <result pre="might enhance early viral control by overcoming virus-imposed innate immune" exact="suppression" post="and facilitating adaptive immune activation. The early timing of"/>
   <result pre="As respiratory mucosal immunity is key to early clearance of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), inducing trained immunity in alveolar macrophages"/>
   <result pre="virus, they have been reported to provide protection against mouse" exact="hepatitis" post="virus, a coronavirus of mice. Notably, these antibodies were"/>
   <result pre="immunity Whereas the current successful human antiviral vaccines, such as" exact="influenza" post="and measles vaccines, depend largely on the induction of"/>
   <result pre="the current successful human antiviral vaccines, such as influenza and" exact="measles" post="vaccines, depend largely on the induction of antibody responses,"/>
   <result pre="SARS-CoV-2 infection is associated not only with virus-mediated innate immune" exact="suppression" post="but also with delayed activation of T cells, particularly"/>
   <result pre="whereas TH2 cell responses have been associated with enhancement of" exact="lung disease" post="following infection in hosts parenterally vaccinated with inactivated SARS-CoV"/>
   <result pre="specific for SARS-CoV-2 and CD4+ T cells specific for human" exact="common cold" post="coronaviruses, SARS-CoV and animal betacoronaviruses17,59–61. There are four human"/>
   <result pre="adults also have IgG antibodies specific for all four human" exact="common cold" post="coronaviruses17. However, similarly to antibody responses to SARS-CoV and"/>
   <result pre="vaccinated with experimental SARS-CoV vaccines. Ferrets vaccinated with a modified" exact="vaccinia virus" post="Ankara (MVA) vaccine expressing full-length S protein had increased"/>
   <result pre="(MVA) vaccine expressing full-length S protein had increased infection and" exact="hepatitis" post="following challenge71,72. Antibodies to S protein were reported to"/>
   <result pre="2 Safety considerations for COVID-19 vaccinesAs most individuals infected with" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) are asymptomatic or develop only mild"/>
   <result pre="known whether it protects against RM viral pathogens Measles and" exact="influenza" post="viruses (replicating) S protein? Quality and durability depend on"/>
   <result pre="Not extensively tested in humans; potential recombination of live attenuated" exact="influenza" post="vectors in the lung delivered via RM route Other"/>
   <result pre="papillomavirus; IM, intramuscular; RBD, receptor-binding domain; RM, respiratory mucosal; SARS-CoV-2," exact="severe acute respiratory syndrome" post="coronavirus 2; S protein, spike protein; SC, subcutaneous; TH"/>
   <result pre="helper cell; TRM cell, resident memory T cell; VSV, vesicular" exact="stomatitis" post="virus. Vaccination routes and regimens In addition to the"/>
   <result pre="this being the primary mechanism by which intramuscular injection of" exact="measles" post="or influenza vaccine offers protection in humans. However, this"/>
   <result pre="the primary mechanism by which intramuscular injection of measles or" exact="influenza" post="vaccine offers protection in humans. However, this route of"/>
   <result pre="repeated doses of IM injection Published data showing prevention of" exact="pneumonia" post="but not transmission in NHPs Published data showing safety"/>
   <result pre="NHP, non-human primate; RBD, receptor-binding domain; saRNA, self-amplifying RNA; SARS-CoV-2," exact="severe acute respiratory syndrome" post="coronavirus 2; S protein, spike protein; TH1 cell, T"/>
   <result pre="spike protein; TH1 cell, T helper 1 cell; VSV, vesicular" exact="stomatitis" post="virus. aSelected for US Operation Warp Speed. Box 3"/>
   <result pre="number of animal species have differing degrees of susceptibility to" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infection, depending on the relative binding"/>
   <result pre="SARS-CoV-2 replication in the lung, and these mice develop interstitial" exact="pneumonia" post="similar to humans188. Human ACE2-expressing mice that are further"/>
   <result pre="attenuated viral vaccines Historically, several successful human vaccines, such as" exact="measles" post="vaccine and the bacillus Calmette–Guérin (BCG) vaccine for tuberculosis"/>
   <result pre="as measles vaccine and the bacillus Calmette–Guérin (BCG) vaccine for" exact="tuberculosis" post="(TB), have been based on attenuated strains of the"/>
   <result pre="on the vaccine strains of other human pathogens (such as" exact="measles" post="or influenza viruses) or veterinary pathogens (such as vesicular"/>
   <result pre="vaccine strains of other human pathogens (such as measles or" exact="influenza" post="viruses) or veterinary pathogens (such as vesicular stomatitis virus"/>
   <result pre="measles or influenza viruses) or veterinary pathogens (such as vesicular" exact="stomatitis" post="virus (VSV)). However, it will be important to consider"/>
   <result pre="nCoV-19 reduced SARS-CoV-2 viral load in the lungs and prevented" exact="pneumonia" post="in rhesus macaques, it did not reduce viral loads"/>
   <result pre="viruses have been used successfully in human vaccines against polio," exact="hepatitis" post="A and influenza121,122. Inactivated viruses can be rapidly generated"/>
   <result pre="in aged hosts56,74,129. Although PiCoVacc or BBIBP-CorV did not worsen" exact="lung disease" post="within 7 days after infection, alum is known to"/>
   <result pre="that are co-expressed or admixed. Several commercial vaccines, such as" exact="hepatitis" post="B and human papillomavirus vaccines, are based on VLPs137."/>
   <result pre="use, their potential is supported by previous studies of influenza," exact="rabies" post="and Zika virus infections in animals149–153. For example, an"/>
   <result pre="virus infections in animals149–153. For example, an mRNA vaccine for" exact="influenza" post="virus induced long-term humoral immunity in young and aged"/>
   <result pre="on the successful experience in respiratory mucosal delivery of influenza," exact="measles" post="and TB vaccines to humans160–162. Respiratory mucosal vaccination also"/>
   <result pre="coronavirus disease 2019 (COVID-19) pandemic and the host response to" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). One scenario is the priority vaccination"/>
   <result pre="rapidly developing lung condition characterized by deficient oxygen exchange and" exact="shortness" post="of breath, resulting from severe lung injury and inflammation"/>
   <result pre="COVID-19 in EuropeNature202058425726132512579 4.SancheSet al.High contagiousness and rapid spread of" exact="severe acute respiratory syndrome" post="coronavirus 2Emerg. Infect. Dis.2020261470147732255761 5.World Health Organization. Draft landscape"/>
   <result pre="sides of the same coin: friends or foes?Front. Immunol.20178196029375577 26.HaqKMcElhaneyJEImmunosenescence:" exact="influenza" post="vaccination and the elderlyCurr. Opin. Immunol.201429384224769424 27.TayMZPohCMRéniaLMacAryPANgLFPThe trinity of"/>
   <result pre="COVID-19Nat. Med.20202684584832350462 41.NakanagaKYamanouchiKFujiwaraKProtective effect of monoclonal antibodies on lethal mouse" exact="hepatitis" post="virus infection in miceJ. Virol.1986591681713012115 42.LecomteJet al.Protection from mouse"/>
   <result pre="hepatitis virus infection in miceJ. Virol.1986591681713012115 42.LecomteJet al.Protection from mouse" exact="hepatitis" post="virus type 3-induced acute disease by an anti-nucleoprotein monoclonal"/>
   <result pre="for protection from clinical disease and for virus clearance in" exact="severe acute respiratory syndrome" post="coronavirus-infected miceJ. Virol.2010849318932520610717 51.TurnerDLet al.Lung niches for the generation"/>
   <result pre="generation and maintenance of tissue-resident memory T cellsMucosal Immunol.2014750151024064670 52.JeyanathanMYaoYAfkhamiSSmaillFXingZNew" exact="tuberculosis" post="vaccine strategies: taking aim at un-natural immunityTrends Immunol.20183941943329429859 53.HaddadiSet"/>
   <result pre="response in SARS coronavirus infectionEmerg. Microbes Infect.2012116 56.BollesMet al.A double-inactivated" exact="severe acute respiratory syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
   <result pre="cells cross-reactive to SARS-CoV-2, likely resulting from previous exposure to" exact="common cold" post="coronaviruses as well as animal coronaviruses. These findings offer"/>
   <result pre="of infection for SARS-CoV-2 countermeasuresNat. Biotechnol.20203878979132504046 71.WeingartlHet al.Immunization with modified" exact="vaccinia virus" post="Ankara-based recombinant vaccine against severe acute respiratory syndrome is"/>
   <result pre="71.WeingartlHet al.Immunization with modified vaccinia virus Ankara-based recombinant vaccine against" exact="severe acute respiratory syndrome" post="is associated with enhanced hepatitis in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation"/>
   <result pre="vaccine against severe acute respiratory syndrome is associated with enhanced" exact="hepatitis" post="in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation of modified vaccinia virus Ankara"/>
   <result pre="associated with enhanced hepatitis in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation of modified" exact="vaccinia virus" post="Ankara based recombinant SARS vaccine in ferretsVaccine2005232273227915755610 73.KamYWet al.Antibodies"/>
   <result pre="pandemicCell Host Microbe20202769970332407708 75.BuchholzUJet al.Contributions of the structural proteins of" exact="severe acute respiratory syndrome" post="coronavirus to protective immunityProc. Natl Acad. Sci.20041019804980915210961 76.StephensenCBCaseboltDBGangopadhyayNNPhylogenetic analysis"/>
   <result pre="coronavirus as a vaccine candidateMBio20134e00650-1324023385 88.NetlandJet al.Immunization with an attenuated" exact="severe acute respiratory syndrome" post="coronavirus deleted in E protein protects against lethal respiratory"/>
   <result pre="in the cytoplasmic tail of spike protein attenuates porcine epidemic" exact="diarrhea" post="virus in pigsJ. Virol.201893e01758-18 90.Jimenez-GuardeñoJMet al.Identification of the mechanisms"/>
   <result pre="a genetically stable vaccinePLoS Pathog.201511e100521526513244 91.MenacheryVDet al.Attenuation and restoration of" exact="severe acute respiratory syndrome" post="coronavirus mutant lacking 2’-O-methyltransferase activityJ. Virol.2014884251426424478444 92.ChengBYHOrtiz-RiañoENogalesAde la TorreJCMartínez-SobridoLDevelopment"/>
   <result pre="placebo-controlled, phase 2 trialLancet202010.1016/S0140-6736(20)31605-632758466 100.SmaillFet al.A human type 5 adenovirus-based" exact="tuberculosis" post="vaccine induces robust T cell responses in humans despite"/>
   <result pre="I trial evaluating the safety and immunogenicity of a candidate" exact="tuberculosis" post="vaccination regimen, ChAdOx1 85A prime – MVA85A boost in"/>
   <result pre="healthy UK adultsVaccine20203877978931735500 114.van DoremalenNet al.ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaquesNature202010.1038/s41586-020-2608-y32731258 115.FolegattiPMet al.Safety and immunogenicity of the"/>
   <result pre="COVID-19 vaccine and therapy plans. Science10.1126/science.abd0121 (2020). 118.CaseJBet al.Replication-competent vesicular" exact="stomatitis" post="virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in miceCell"/>
   <result pre="against SARS-CoV-2 challengebioRxiv202010.1101/2020.06.18.160655 120.KochTet al.Safety and immunogenicity of a modified" exact="vaccinia virus" post="Ankara vector vaccine candidate for Middle East respiratory syndrome:"/>
   <result pre="vaccine: past and present experienceVaccine1996147357468817819 122.VellozziCet al.Safety of trivalent inactivated" exact="influenza" post="vaccines in adults: background for pandemic influenza vaccine safety"/>
   <result pre="of trivalent inactivated influenza vaccines in adults: background for pandemic" exact="influenza" post="vaccine safety monitoringVaccine2009272114212019356614 123.WoodJMRobertsonJSFrom lethal virus to life-saving vaccine:"/>
   <result pre="in mice after immunization with the S2 subunit of the" exact="severe acute respiratory syndrome" post="coronavirusDNA Cell Biol.20052451051516101349 134.ZhouYJiangSDuLProspects for a MERS-CoV spike vaccineExpert."/>
   <result pre="formulation for clinical translationExpert. Rev. Vaccines20181783384930173619 138.LuXet al.Immune responses against" exact="severe acute respiratory syndrome" post="coronavirus induced by virus-like particles in miceImmunology200712249650217680799 139.LokugamageKGet al.Chimeric"/>
   <result pre="by virus-like particles in miceImmunology200712249650217680799 139.LokugamageKGet al.Chimeric coronavirus-like particles carrying" exact="severe acute respiratory syndrome" post="coronavirus (SCoV) S protein protect mice against challenge with"/>
   <result pre="al.Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infectionNat. Biotechnol.2012301210121623159882 150.ChahalJSet al.Dendrimer-RNA nanoparticles generate protective"/>
   <result pre="doseProc. Natl Acad. Sci. USA2016113E4133E414227382155 151.SchneeMet al.An mRNA vaccine encoding" exact="rabies" post="virus glycoprotein induces protection against lethal infection in mice"/>
   <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="virusesMol. Ther.2017251316132728457665 153.PardiNet al.Zika virus protection by a single"/>
   <result pre="mouse modelSci. Rep.2017725228325910 155.AlbererMet al.Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
   <result pre="vaccine protection against SARS-CoV-2 in rhesus macaquesScience202010.1126/science.abc628432820126 159.LichtyBDBreitbachCJStojdlDFBellJCGoing viral with" exact="cancer" post="immunotherapyNat. Rev. Cancer20141455956724990523 160.MohnKG-ISmithISjursenHCoxRJImmune responses after live attenuated influenza"/>
   <result pre="with cancer immunotherapyNat. Rev. Cancer20141455956724990523 160.MohnKG-ISmithISjursenHCoxRJImmune responses after live attenuated" exact="influenza" post="vaccinationHum. Vaccin. Immunother.20181457157828933664 161.LowNet al.A randomized, controlled trial of"/>
   <result pre="Engl. J. Med.20153721519152925875257 162.SattiIet al.Safety and immunogenicity of a candidate" exact="tuberculosis" post="vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults:"/>
   <result pre="with trained immunityCell Host Microbe20182389100.e529324233 175.VerrallAJet al.Early clearance of mycobacterium" exact="tuberculosis" post="is associated with increased innate immune responsesJ. Infect. Dis.201922113421350"/>
   <result pre="memory in barrier tissuesNat. Rev. Immunol.20202030832032015472 180.CardaniABoultonAKimTSBracialeTJAlveolar macrophages prevent lethal" exact="influenza" post="pneumonia by inhibiting infection of type-1 alveolar epithelial cellsPLoS"/>
   <result pre="in barrier tissuesNat. Rev. Immunol.20202030832032015472 180.CardaniABoultonAKimTSBracialeTJAlveolar macrophages prevent lethal influenza" exact="pneumonia" post="by inhibiting infection of type-1 alveolar epithelial cellsPLoS Pathog.201713e100614028085958"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7473047/results/search/disease/results.xml">
   <result pre="ref-count: page-count: Introduction In December 2019, an unprecedented outbreak of" exact="pneumonia" post="cases of unknown aetiology was identified in Wuhan City,"/>
   <result pre="deaths worldwide [4]. COVID-19 is caused by the infection of" exact="severe acute respiratory syndrome" post="coronavirus-2 (SARS-CoV-2), which potently elicits pulmonary hyper-inflammation and infiltration,"/>
   <result pre="and similar public health emergencies such as SARS and H1N1" exact="influenza" post="in China were extensively used and played very important"/>
   <result pre="were eligible patients with positive RT–PCR result for SARS-CoV-2 and" exact="pneumonia" post="confirmed by chest imaging. The top 3 disease conditions"/>
   <result pre="external reference comparator [18]. For a novel emerging acute respiratory" exact="infectious disease," post="it was unable to gather any reliable, comparable, and"/>
   <result pre="States have shown early promising benefits in cases with severe" exact="pneumonia" post="[26,27]. A phase III clinical trial of remdesivir for"/>
   <result pre="reported by the author(s). References References 1LuH, StrattonCW, TangYW.Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
   <result pre="PubMed PMID: 31950516. doi: 10.1002/jmv.2567831950516 2ZhouP, YangXL, WangXG, et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
   <result pre="and core measures for prevention and control of novel coronavirus" exact="pneumonia" post="in China. Zhonghua Yu Fang Yi Xue Za Zhi."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7474482/results/search/disease/results.xml">
   <result pre="of COVID-19 as a global pandemic. Background Spread of the" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2; COVID-19) pandemic has been unprecedented and"/>
   <result pre="(BCG) vaccine, the third dose of the diphtheria, tetanus, and" exact="pertussis" post="(DTP) vaccine, the oral polio (OPV3) vaccine, and the"/>
   <result pre="oral polio (OPV3) vaccine, and the first dose of the" exact="measles" post="vaccine [2]. However, in a recent report (15 July"/>
   <result pre="backslide in vaccination rates [4]. In addition, 30 campaigns for" exact="measles" post="and rubella vaccination are at risk of being cancelled,"/>
   <result pre="vaccination rates [4]. In addition, 30 campaigns for measles and" exact="rubella" post="vaccination are at risk of being cancelled, which will"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7479474/results/search/disease/results.xml">
   <result pre="superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as" exact="tuberculosis" post="(TB), which remains a significant disease for public health"/>
   <result pre="were discussed. First, lessons from past outbreaks (other coronaviruses) and" exact="influenza" post="pandemic/seasonal outbreaks have taught the importance of infection control"/>
   <result pre="1. Introduction The global threat of contagious infectious diseases, particularly" exact="tuberculosis" post="(TB), has long concerned authorities in charge of public"/>
   <result pre="namely, a large number of severe forms, cases with multidrug-resistant" exact="tuberculosis" post="(MDR-TB) and extensively drug-resistant TB (XDR-TB), HIV coinfection, and"/>
   <result pre="[4]. Influenza infection may promote the progression of latent Mycobacterium" exact="tuberculosis" post="(MTB) infection to active TB, alter the clinical presentation"/>
   <result pre="TB, and also possibly exacerbate pulmonary TB (PTB) [6]. Both" exact="influenza" post="and tuberculosis hinder host immune responses. Specifically, influenza can"/>
   <result pre="also possibly exacerbate pulmonary TB (PTB) [6]. Both influenza and" exact="tuberculosis" post="hinder host immune responses. Specifically, influenza can impair T-cell"/>
   <result pre="[6]. Both influenza and tuberculosis hinder host immune responses. Specifically," exact="influenza" post="can impair T-cell immunity and weaken innate immune responses"/>
   <result pre="mortality, and patients with PTB may increase the severity of" exact="influenza" post="disease and death due to chronic lung disease and"/>
   <result pre="the severity of influenza disease and death due to chronic" exact="lung disease" post="and immunosuppression. Epidemiologic data suggest an increased rate of"/>
   <result pre="disease and immunosuppression. Epidemiologic data suggest an increased rate of" exact="influenza" post="or severe influenza-associated disease in patients with TB during"/>
   <result pre="influenza or severe influenza-associated disease in patients with TB during" exact="influenza" post="pandemics [6, 8, 9] or during seasonal influenza epidemics"/>
   <result pre="TB during influenza pandemics [6, 8, 9] or during seasonal" exact="influenza" post="epidemics [10] compared with non-TB individuals. 2. Objectives Individuals"/>
   <result pre="TB sequelae based on the data available from the past" exact="influenza" post="pandemic and seasonal influenza outbreaks (considering similar or more"/>
   <result pre="the data available from the past influenza pandemic and seasonal" exact="influenza" post="outbreaks (considering similar or more severe outcomes in the"/>
   <result pre="three human coronaviruses known to cause fatal respiratory diseases: The" exact="severe acute respiratory syndrome" post="(SARS) coronavirus (SARS-CoV, now known as SARS-CoV-1) that led"/>
   <result pre="only three months since the first declared case of COVID-19" exact="pneumonia" post="[16]. Its high transmissibility rate reminds of the 1918-19"/>
   <result pre="pneumonia [16]. Its high transmissibility rate reminds of the 1918-19" exact="influenza" post="pandemic when it has been estimated that almost a"/>
   <result pre="a mortality rate of 2.5% [9]. Other significant differences between" exact="influenza" post="pandemics and current novel coronavirus pandemic can be found."/>
   <result pre="is that death was less frequent amidst healthcare workers in" exact="influenza" post="pandemics as it was the case in SARS, MERS,"/>
   <result pre="[17]. Despite this, other similarities still exist between SARS-CoV-2 and" exact="influenza" post="as the striking resemblance of pathological features documented in"/>
   <result pre="the striking resemblance of pathological features documented in COVID-19 associated" exact="acute respiratory distress syndrome" post="(ARDS) and H7N9-induced ARDS [18]. Also, it has been"/>
   <result pre="and H7N9-induced ARDS [18]. Also, it has been suggested that" exact="influenza" post="viruses, as well as SARS-CoV-2, significantly upregulate angiotensin-converting enzyme"/>
   <result pre="entrance into the host cell and makes patients infected by" exact="influenza" post="more susceptible to SARS-CoV-2. Some studies have shown that,"/>
   <result pre="with TB, induction of type I interferons (IFNs) determined by" exact="influenza" post="infection could be detrimental [11], impeding the immune-competent host's"/>
   <result pre="the infection [19] and precipitates TB mortality rate (pneumonia and" exact="influenza" post="death rates among the age group most affected by"/>
   <result pre="death rates were noted in winter months (coinciding with seasonal" exact="influenza" post="outbreaks), which led to the suggestion of PTB being"/>
   <result pre="mortality [10]. In contrast, few studies suggested no association between" exact="influenza" post="coinfection and PTB's progression or severity [20, 21]. One"/>
   <result pre="or severity [20, 21]. One murine model demonstrated that although" exact="influenza" post="infection increased the IFN-γ secretion, it had little effect"/>
   <result pre="included in a recent systematic review showed no evidence on" exact="influenza" post="affecting PTB presentation or its outcomes or, conversely, PTB"/>
   <result pre="affecting PTB presentation or its outcomes or, conversely, PTB affecting" exact="influenza" post="presentation and outcomes [6]. Nevertheless, the magnitude of TB"/>
   <result pre="[25], data compatible with previous studies on mice regarding the" exact="suppression" post="of cellular immunity after a viral infection [11]. There"/>
   <result pre="[29]. Immune system hyperreaction was also described in the 1918–1919" exact="influenza" post="pandemic, which was the first known pandemic to report"/>
   <result pre="are highly similar might be premature, few studies proved that" exact="influenza" post="aggravated the pulmonary status of individuals with TB so"/>
   <result pre="with mutations in the IFN-γ and IL-12 signaling pathways and" exact="rheumatoid arthritis" post="or Crohn's disease patients treated with TNF-α blockade [19,"/>
   <result pre="mutations in the IFN-γ and IL-12 signaling pathways and rheumatoid" exact="arthritis" post="or Crohn's disease patients treated with TNF-α blockade [19,"/>
   <result pre="TB status might play a role in the development of" exact="severe acute respiratory syndrome" post="in SARS-CoV-2 coinfection, considering the cases described in China"/>
   <result pre="aggravated, and only four patients had signs of newly developed" exact="pneumonia" post="[37]. One should keep in mind that the existence"/>
   <result pre="was suggested that populations with a high risk of contracting" exact="influenza" post="or SARS might also have a higher prevalence of"/>
   <result pre="treatments [41]. Discontinuation risks and other challenges faced by the" exact="tuberculosis" post="clinical trials in the face of COVID-19 have been"/>
   <result pre="the clinical and imagistic similarities such as cough, fever, or" exact="shortness" post="of breath and various radiological pulmonary lesions [4, 22],"/>
   <result pre="either be facing a steep differential diagnostic or not consider" exact="tuberculosis" post="at all. Considering the sudden onset of the SARS-CoV-2"/>
   <result pre="with a higher risk of nontuberculous mycobacterial (NTM) infection in" exact="rheumatoid arthritis" post="patients [14]. 4.4.1. Key Points Coinfection of TB and"/>
   <result pre="a higher risk of nontuberculous mycobacterial (NTM) infection in rheumatoid" exact="arthritis" post="patients [14]. 4.4.1. Key Points Coinfection of TB and"/>
   <result pre="likely affects both sides of these patients: rapid development of" exact="severe acute respiratory syndrome" post="through cytokine-mediated immune response and increased risk of tuberculosis"/>
   <result pre="respiratory syndrome through cytokine-mediated immune response and increased risk of" exact="tuberculosis" post="reactivation. As a lesson from previous outbreaks, hospital treatment"/>
   <result pre="a lesson from previous outbreaks, hospital treatment for patients with" exact="tuberculosis" post="should be limited to severe cases, to prevent the"/>
   <result pre="and embryology=Revue roumaine de morphologie et embryologie201758238539228730222 6WalazaS.CohenC.TempiaS.et al.Influenza and" exact="tuberculosis" post="co-infection: a systematic reviewInfluenza and Other Respiratory Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC."/>
   <result pre="cell responses in the lungThe Journal of Immunology201018442048205610.4049/jimmunol.090277220083661 8NoymerA.The 1918" exact="influenza" post="pandemic hastened the decline of tuberculosis in the United"/>
   <result pre="of Immunology201018442048205610.4049/jimmunol.090277220083661 8NoymerA.The 1918 influenza pandemic hastened the decline of" exact="tuberculosis" post="in the United States: an age, period, cohort analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102"/>
   <result pre="United States: an age, period, cohort analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102 9OeiW.NishiuraH.The relationship between" exact="tuberculosis" post="and influenza death during the influenza (H1N1) pandemic from"/>
   <result pre="an age, period, cohort analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102 9OeiW.NishiuraH.The relationship between tuberculosis and" exact="influenza" post="death during the influenza (H1N1) pandemic from 1918-19Computational and"/>
   <result pre="analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102 9OeiW.NishiuraH.The relationship between tuberculosis and influenza death during the" exact="influenza" post="(H1N1) pandemic from 1918-19Computational and Mathematical Methods in Medicine2012201210.1155/2012/124861"/>
   <result pre="Mathematical Methods in Medicine2012201210.1155/2012/124861 10WalazaS.CohenC.NanooA.CohenA. L.McAnerneyJ.von MollendorfC.Excess mortality associated with" exact="influenza" post="among tuberculosis deaths in South Africa, 1999–2009PLoS One201510610.1371/journal.pone.0129173 11RedfordP."/>
   <result pre="in Medicine2012201210.1155/2012/124861 10WalazaS.CohenC.NanooA.CohenA. L.McAnerneyJ.von MollendorfC.Excess mortality associated with influenza among" exact="tuberculosis" post="deaths in South Africa, 1999–2009PLoS One201510610.1371/journal.pone.0129173 11RedfordP. S.Mayer-BarberK. D.McNabF."/>
   <result pre="S.Mayer-BarberK. D.McNabF. W.et al.Influenza A virus impairs control of Mycobacterium" exact="tuberculosis" post="coinfection through a type I interferon receptor-dependent pathwayThe Journal"/>
   <result pre="Influenza A (H1N1)2009Geneva, SwitzerlandWHOhttp://www9.who.int/tb/features_archive/h1n1/en/ 13LiJ.-Y.YouZ.WangQ.et al.The epidemic of 2019-novel-coronavirus (2019-nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the futureMicrobes"/>
   <result pre="D.SherA.Cytokine and lipid mediator networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent" exact="influenza" post="virus infection and tuberculosis in patients hospitalized with respiratory"/>
   <result pre="networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent influenza virus infection and" exact="tuberculosis" post="in patients hospitalized with respiratory illness in ThailandInfluenza and"/>
   <result pre="H.KarmanJ.et al.Interactions between T cells responding to concurrent mycobacterial and" exact="influenza" post="infectionsThe Journal of Immunology2006177128456846510.4049/jimmunol.177.12.845617142743 22RaoultD.ZumlaA.LocatelliF.IppolitoG.KroemerG.Coronavirus infections: epidemiological, clinical and"/>
   <result pre="C.ZumlaA.Severe acute respiratory syndromeInfectious Disease Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary" exact="tuberculosis" post="and SARS, ChinaEmerging Infectious Disease Journal2006124p. 707 25LowJ. G."/>
   <result pre="respiratory syndromeThe Journal of Infectious Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of Mycobacterium" exact="tuberculosis" post="found through screening for severe acute respiratory syndrome—Taipei, Taiwan,"/>
   <result pre="28AlfarajS. H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East respiratory syndrome coronavirus and" exact="pulmonary tuberculosis" post="coinfection: implications for infection controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC."/>
   <result pre="H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East respiratory syndrome coronavirus and pulmonary" exact="tuberculosis" post="coinfection: implications for infection controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC."/>
   <result pre="casesEuropean Respiratory Journal202056110.1183/13993003.01398-2020 31HarrisJ.KeaneJ.How tumour necrosis factor blockers interfere with" exact="tuberculosis" post="immunityClinical and Experimental Immunology201016111920491796 32OrganizationW. H.Addressing the Needs of"/>
   <result pre="coronavirus infection: pathological interrelationshipIndian Journal of Tuberculosis2020672p. 26410.1016/j.ijtb.2020.02.004 35GaoY.LiuM.ChenY.ShiS.GengJ.TianJ.Association between" exact="tuberculosis" post="and COVID-19 severity and mortality: a rapid systematic review"/>
   <result pre="from two cohortsPulmonology202026423324010.1016/j.pulmoe.2020.05.00232411943 37StochinoC.VillaS.ZucchiP.ParraviciniP.GoriA.RaviglioneM. C.Clinical characteristics of COVID-19 and active" exact="tuberculosis" post="co-infection in an Italian reference hospitalEuropean Respiratory Journal202056110.1183/13993003.01708-2020 38JohnR."/>
   <result pre="schedulingEmerging Infectious Disease Journal2006121p. 159 39HardingE.WHO global progress report on" exact="tuberculosis" post="eliminationThe Lancet Respiratory Medicine202081p. 1910.1016/s2213-2600(19)30418-7 40AmimoF.LambertB.MagitA.What does the COVID-19"/>
   <result pre="40AmimoF.LambertB.MagitA.What does the COVID-19 pandemic mean for HIV, tuberculosis, and" exact="malaria" post="control?Tropical Medicine and Health2020481p. 3210.1186/s41182-020-00219-6 41ManyazewalT.WoldeamanuelY.BlumbergH. M.FekaduA.MarconiV. C.The fight"/>
   <result pre="Medicine and Health2020481p. 3210.1186/s41182-020-00219-6 41ManyazewalT.WoldeamanuelY.BlumbergH. M.FekaduA.MarconiV. C.The fight to end" exact="tuberculosis" post="must not be forgotten in the COVID-19 outbreakNature Medicine202026681181210.1038/s41591-020-0917-1"/>
   <result pre="be forgotten in the COVID-19 outbreakNature Medicine202026681181210.1038/s41591-020-0917-1 42RusenI. D.Challenges in" exact="tuberculosis" post="clinical trials in the face of the COVID-19 pandemic:"/>
   <result pre="success and failure of BCG - implications for a novel" exact="tuberculosis" post="vaccineNature Reviews Microbiology20053865666210.1038/nrmicro121116012514 51AabyP.BennC. S.Saving lives by training innate"/>
   <result pre="64LuL. L.SmithM. T.YuK. K. Q.et al.IFN-γ-independent immune markers of Mycobacterium" exact="tuberculosis" post="exposureNature Medicine201925697798710.1038/s41591-019-0441-3 65WhittakerE.López-VarelaE.BroderickC.SeddonJ. A.Examining the complex relationship between tuberculosis"/>
   <result pre="Mycobacterium tuberculosis exposureNature Medicine201925697798710.1038/s41591-019-0441-3 65WhittakerE.López-VarelaE.BroderickC.SeddonJ. A.Examining the complex relationship between" exact="tuberculosis" post="and other infectious diseases in childrenFrontiers in Pediatrics2019723310.3389/fped.2019.00233 66YamasueM.KomiyaK.UsagawaY.UmekiK.NurekiS.-i.AndoM.Factors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7480895/results/search/disease/results.xml">
   <result pre="infect a wide host range to produce disease ranging from" exact="common cold" post="to severe/fatal illness [2]. The SARS-COV-2 genome consists of"/>
   <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan [published correction appearsEmerg Microbes Infect20209122123610.1080/22221751.2020.171990231987001 4.YuanYCaoDZhangYet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7482990/results/search/disease/results.xml">
   <result pre="novel coronavirus referred to as coronavirus disease 2019 (COVID-19) or" exact="severe acute respiratory syndrome" post="2 (COVID-19 or SARS-COV2) continues to devastate the world."/>
   <result pre="proposed that Bacillus Calmette-Guérin (BCG) vaccination provides some protection against" exact="viral disease." post="This vaccine has been utilized since the early 1920s;"/>
   <result pre="nations have adopted compulsory BCG vaccination protocols for prophylaxis of" exact="tuberculosis" post="(TB) over the past few decades which at the"/>
   <result pre="showed to enhance immunity against pathogens such as listeria and" exact="influenza" post="in mice models [22,23]. The underlying mechanism for this"/>
   <result pre="beneficial effect of BCG?VaccineGarlyMLMartinsCLBaléCet al.2782279021200312798618 22Nonspecific protection of mice against" exact="influenza" post="virus infection by local or systemic immunization with Bacille"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7489243/results/search/disease/results.xml">
   <result pre="emergence of coronavirus disease 2019 (COVID-19), which is caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), has caused a large-scale global outbreak"/>
   <result pre="rates in COVID-19 patients are associated with underlying comorbidities, including" exact="cardiovascular disease," post="diabetes, hypertension, and chronic obstructive pulmonary disease [10]. Remarkably,"/>
   <result pre="associated with underlying comorbidities, including cardiovascular disease, diabetes, hypertension, and" exact="chronic obstructive pulmonary disease" post="[10]. Remarkably, there is a bidirectional relationship between COVID-19"/>
   <result pre="proposed that SARS-CoV may damage islets and cause acute insulin-dependent" exact="diabetes mellitus" post="[16]. Whether there is a link between the development"/>
   <result pre="[25]. In a human challenge trials (HCTs) of an oral" exact="influenza" post="vaccine using adenovirus as a carrier, the levels of"/>
   <result pre="levels of binding antibody and neutralizing antibody of the adenovirus-vectored" exact="influenza" post="vaccine were lower than those of an inactivated vaccine,"/>
   <result pre="while the T-cell response and IgA level of the adenovirus-vectored" exact="influenza" post="vaccine were remarkably higher than those of the inactivated"/>
   <result pre="of the inactivated vaccine. The protection rate of the adenovirus-vectored" exact="influenza" post="vaccine was found to be significantly higher than that"/>
   <result pre="the cellular immune and IgA responses generated by an adenovirus-vectored" exact="influenza" post="vaccine play important roles in preventing influenza virus infection"/>
   <result pre="by an adenovirus-vectored influenza vaccine play important roles in preventing" exact="influenza" post="virus infection [26]. These findings suggest that a vaccine’s"/>
   <result pre="protection against respiratory viral diseases in most cases, such as" exact="influenza" post="and respiratory syncytial virus [27], [28]. The delivery route"/>
   <result pre="induction of local mucosal immunity. Studies on a live attenuated" exact="influenza" post="vaccine found that intranasal delivery of vaccination was more"/>
   <result pre="to enhance the immune responses of the elderly; examples include" exact="hepatitis" post="B vaccines and influenza vaccines [34], [35]. An ideal"/>
   <result pre="responses of the elderly; examples include hepatitis B vaccines and" exact="influenza" post="vaccines [34], [35]. An ideal candidate COVID-19 vaccine should"/>
   <result pre="challenged (whether or not they have been vaccinated) with an" exact="infectious disease" post="organism, such as SARS-CoV-2. The use of controlled HCTs—instead"/>
   <result pre="neutralizing antibody titersNat Med266202093294032393800 23YangZ.-y.WernerH.C.KongW.-p.LeungK.TraggiaiE.LanzavecchiaA.NabelG.J.Evasion of antibody neutralization in emerging" exact="severe acute respiratory syndrome" post="coronavirusesProceedings of the National Academy of Sciences10232005797801 24JinH.XiaoC.ChenZ.e.KangY.MaY.ZhuK.XieQ.TuY.YuY.WangB.Induction of"/>
   <result pre="11 years post-infectionVaccine341720162008201426954467 26LiebowitzD.GottliebK.KolhatkarN.S.GargS.J.AsherJ.M.NazarenoJ.KimK.McIlwainD.R.TuckerS.N.Efficacy, immunogenicity, and safety of an oral" exact="influenza" post="vaccine: a placebo-controlled and active-controlled phase 2 human challenge"/>
   <result pre="challenge studyThe Lancet Infectious Diseases204202043544431978354 27van RietE.AinaiA.SuzukiT.HasegawaH.Mucosal IgA responses in" exact="influenza" post="virus infections; thoughts for vaccine designVaccine304020125893590022835738 28HuK.-F.Lövgren-BengtssonK.MoreinB.Immunostimulating complexes (ISCOMs)"/>
   <result pre="Xing Bing Xue Za Zhi 2020;41(2):145–51. Chinese. 31SharmaP.KumarA.Metabolic dysfunction associated" exact="fatty liver disease" post="increases risk of severe Covid-19Diabetes &amp;amp; Metabolic Syndrome: Clinical"/>
   <result pre="Bing Xue Za Zhi 2020;41(2):145–51. Chinese. 31SharmaP.KumarA.Metabolic dysfunction associated fatty" exact="liver disease" post="increases risk of severe Covid-19Diabetes &amp;amp; Metabolic Syndrome: Clinical"/>
   <result pre="the COVID-19 pandemicHeart1061720201296130132444504 34EdelmanR.DemingM.E.ToapantaF.R.HeuserM.D.ChrisleyL.BarnesR.S.WassermanS.S.BlackwelderW.C.HandwergerB.S.PasettiM.SiddiquiK.M.SzteinM.B.The SENIEUR protocol and the efficacy of" exact="hepatitis" post="B vaccination in healthy elderly persons by age, gender,"/>
   <result pre="Yan B. Yang X. Yang Effectiveness, immunogenicity, and safety of" exact="influenza" post="vaccines with MF59 adjuvant in healthy people of different"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7499491/results/search/disease/results.xml">
   <result pre="existing copyright protections.ciaa1223.pdf Abstract Abstract Background The Bacille Calmette-Guérin (BCG)" exact="tuberculosis" post="vaccine has immunity benefits against respiratory infections. Accordingly, it"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="covid_vaccine/PMC7499784/results/search/disease/results.xml">
   <result pre="they have been implicated in recent resurgences of polio and" exact="measles" post="[8,9]. Some preliminary evidence suggests that COVID-19 conspiracy beliefs"/>
   <result pre="A previous nationally representative study documented a 14% gap in" exact="influenza" post="vaccine uptake among participants who disbelieved medical conspiracies versus"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
